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INVESTIGATION OF A ROLE FOR IKAROS IN REPRESSING THE TYPE-I 
INTERFERON RESPONSE GENE PROGRAM IN T-CELLS 
NICOLE DEROSIA 
ABSTRACT 
 Ikaros is a transcription factor expressed in blood cells. Germline Ikaros 
mutations yield abnormal T cells due to defects in T cell maturation. Therefore, to study 
the role of Ikaros in mature CD4+ T cells, a conditional knockout mouse was developed 
such that Ikaros is expressed until CD4+ T cells have matured. Ikaros-deficient CD4+ T 
cells from these mice have a phenotype which is associated with inflammatory diseases 
and autoimmunity. In experiments described in this thesis, I show that lack of Ikaros in 
CD4+ T cells results in the upregulation of type I interferon (IFN)-induced gene 
programs. Upregulation in interferon sensitive genes (ISGs) is not due to environmental 
cues since α/β receptor (IFNAR1) signaling pathways are not activated. In addition, the 
phenotype is localized to CD4+ T cells containing the Ikaros mutation, as increased ISG 
expression is not observed in macrophages. Enhanced ISG expression also impairs the 
ability of Ikaros-deficient CD4+ T cells to be infected with virus. In addition, the Ikaros 
conditional knockout mice showed an increased population of CD11b+ T cells in the 
spleen, which may be related to the increase in ISG expression, as cells with this 
phenotype arise during viral infection when type I IFN expression would be high. 
Furthermore, we were able to obtain human Jurkat cell lines with CRISPR engineered 
Ikaros knockouts. However, I was unable to confirm that Ikaros was successfully 
knocked out in these cell lines. Taken together, these data demonstrate a role for Ikaros in 
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the repression of type I IFN gene programs, which are critical for preventing and fighting 
viral infections, and also play a role in autoimmunity. Ikaros may also play a role in the 
regulation of CD11b+ T cell populations, which remains to be explored.  
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INTRODUCTION 
Maturation of CD4+ T Cells 
CD4+ T cells are cells within the adaptive immune system that play a crucial role 
in regulation of the immune response to pathogens. T cells coordinate the immune 
response through several means: they regulate the function of macrophages in the innate 
immune system; they intensify responses of CD8+ T cells; they aid B cells in the 
production of antibodies; and they control immune responses and prevent autoimmunity 
by adjusting the magnitude and persistence of an immune response (Zhu et al., 2010).  
T cells begin as hematopoietic stem cells in the bone marrow. Once committed to 
the lymphoid lineage, they travel to the thymus where they lose their potential to become 
either B cells or natural killer cells. These now double negative thymocytes, which 
express neither CD4 nor CD8, can become either αβ T cell receptor (TCR)-expressing 
cells or γδ TCR-expressing cells. The αβ TCR-expressing cells go through β-selection 
and become double positive expressers of CD4 and CD8. These double positive 
thymocytes then migrate through positive and negative selection. Cells that are positively 
selected become either CD4+ or CD8+ mature T cells. After undergoing selection, the 
cells travel to the spleen. CD4+ helper T cells express CD4 and major histocompatibility 
complex (MHC) class II-restricted receptors while CD8+ cytotoxic T cells express CD8 
and MHC class I-restricted receptors (Germain, 2002).  
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The Ikaros Protein 
 Ikaros is a zinc-finger protein critical for the maturation of lymphocytes (Wang et 
al., 1996). The gene contains eight exons and undergoes alternative splicing, resulting in 
the creation of eight isoforms of the protein. Exons 3, 4, and 5 contain zinc-finger motifs 
critical for DNA binding, and exon 8 contains two zinc-finger domains critical for 
protein-protein interactions. Not all isoforms contain exons 3 through 5, but exon 8 is 
present in all isoforms, as the protein-protein interactions are necessary for all isoforms 
because it allows the proteins to dimerize with either the same or different isoforms (Sun, 
Liu, & Georgopoulos, 1996; Molnar et al., 1996; Molnar & Georgopoulos, 1994). Ikaros 
is highly expressed in hematopoietic stem cells and blood cell lineages, and is necessary 
for the proper maturation of blood cell lineages, including CD4+ T cells.  
Hematopoietic stem cells in genetically engineered Ikaros null mice have an 
impaired ability to commit to the lymphoid lineage, and thymocytes have impaired 
positive and negative selection (Wang et al., 1996; Urban, Brugmann, & Winandy, 2009; 
Urban & Winandy, 2004; Winandy et al., 1999). Ikaros null CD4+ T cells also show 
defects in differentiation into the different subsets of helper T cells (Quirion et al., 2009; 
Wong, Hatfield, & Brown, 2013; Agnihotri et al., 2017; Avitahl et al., 1999), and all 
mice eventually develop leukemias and lymphomas that arise in the thymus (Wang et al., 
1996). This created a need to develop a mouse model in which Ikaros is conditionally 
knocked out in mature T cells (Lyon de Ana et al., 2019). This conditional knockout 
would provide a mouse model in which the T cells can mature with normal expression of 
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Ikaros as in the wild type, before having Ikaros knocked out in the mature T cells. One 
effective method to achieve this is the Cre/loxP system.  
 
Genetic Engineering: Cre/loxP and CRISPR/Cas9 Systems 
The Cre/loxP system is a method used to create a tissue or cell-specific gene 
mutation which can be induced at different stages of ontogeny. This method involves 
breeding two mice, one containing the gene of interest flanked by 34 base pair loxP sites 
(“floxed gene”) and the other a transgene expressing Cre recombinase from a cell-
specific or inducible promoter. Cre recombinase generates site-specific recombination 
through recognition of loxP sites. The protein brings the loxP sites together and excises 
or inverts the gene sequence between the loxP sites, causing the knockout or mutation. 
The gene for Cre recombinase is linked to the promoter necessary for the desired timing 
and cell-specific expression (Kos, 2004).  
 Another method used for genomic engineering is the CRISPR/Cas9 system, 
originally discovered as a method of adaptive immunity in prokaryotes. Within their 
genomes lies a clustered regularly interspaced short palindromic repeat (CRISPR) region 
characterized by spacers, in between which are short repetitive sequences (Fig. 1A). The 
spacers contain foreign DNA which was spliced and integrated into the genome (Fig. 
1B). After incorporation into the DNA, the CRISPR region is transcribed, generating 
precursor CRISPR-RNA (pre-crRNA). TracrRNA and Cas9 are transcribed along with it, 
as they lie upstream of the CRISPR region.  
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Figure 1.  The CRISPR/Cas9 system in prokaryotic cells. 
(A) The prokaryotic cell contains within its genome a CRISPR region characterized by 
spacers and repeats.  The guide for TracrRNA and Cas9 are located upstream of this 
region. (B) Upon infection with foreign DNA, the DNA is spliced and incorporated into 
the CRISPR region as a spacer. (C) The CRISPR region, Cas9, and TracrRNA are 
transcribed to form TracrRNA, Cas9, and pre-crRNA. Pre-crRNA binds to TracrRNA, 
Cas9, and present RNase III to form crRNA. RNase III splices the crRNA to form 
crRNPs. (D) Upon repeated infection, the crRNP specific to the foreign DNA (as 
encoded by the spacer) binds to the foreign DNA, which is then cleaved by Cas9.  
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Pre-crRNA is matured to crRNA when bound with tracrRNA, RNase III, and Cas9 (Lone 
et al., 2018). TracrRNA is non-encoding and binds to the pre-crRNA transcript. 
Following this, RNase III binds as well, along with Cas9, and splices the transcript 
(Chylinski, Rhun, & Charpentier, 2013) (Fig. 1C). The now mature Cas9-crRNA-
tracrRNA ribonucleoprotein (crRNP) can interfere with foreign DNA upon repeated 
infection by binding to the DNA matching the encoded spacer within the complex. Cas9 
cleaves the double stranded DNA target, causing degradation of the target (Fig. 1D). This 
can be taken advantage of to achieve gene cleavage in mammalian cells. This is done by 
modifying the crRNP complex using single guide RNA (sgRNA) specific to the target 
site of interest. A plasmid containing the template for this new sgRNA is cloned into the 
plasmid which expresses Cas9, and this plasmid is introduced to the mammalian cell. 
Genome editing then occurs when transcription of Cas9 is activated, the DNA is cleaved, 
and then repaired through either nonhomologous end joining or homology-directed repair 
(Lone et al., 2018).  
 
The Type I IFN Response  
There are three classes of interferons (IFNs), classified based on the cell surface 
receptor with which they interact, and which genes and cytokines they upregulate. In 
mammalian cells, the immune system is activated by the presence of pathogens, and the 
type I IFN response acts as protection against invading viruses. Infection of mammalian 
cells with a virus induces the expression of the type I IFNs, IFN-α and IFN-β.  
 7 
 
 
 
Figure 2.  The type I IFN response. 
(1). IFN-α or IFN-β binds to IFNAR complex, causing it to dimerize. (2) TYK2 and 
JAK2 autophosphorylate and the IFNAR1 complex becomes phosphorylated. (3) STAT1 
and STAT2 dock to the IFNAR1 complex and are phosphorylated by TYK2 and JAK2. 
(4) STAT1 and STAT2 dimerize, and bind to IRF-9, forming the ISGF3 complex. (5) 
The ISGF3 complex moves to the nucleus and binds to ISGs containing an ISRE, 
resulting in the transcription of ISGs. 
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Type I IFNs then bind to the type I α/β receptor (IFNAR1) cell surface receptor, causing 
signal transduction and activation of interferon-sensitive genes (ISGs). The major 
effector of the type I IFN response is the JAK/STAT pathway. Type I IFNs bind to 
IFNAR1, a dimeric receptor complex, resulting in a conformational shift in the complex. 
This causes activation of the Janus kinases JAK1 and TYK2 through 
autophosphorylation, followed by their phosphorylation of tyrosine residues within 
INFAR1. These phosphorylated sites now act as anchors to which the STAT1 and 
STAT2 transcription factors bind. JAK1 and TYK2 then phosphorylate STAT1 and 
STAT2, which release and become a heterodimer. The heterodimer complex binds with 
IRF-9, forming the ISGF3 complex, which then travels to the nucleus and binds to 
promoters of ISGs, causing an upregulation of their expression (Fig. 2). Activation of this 
pathway results in expression of ISGs that provide antiviral effects by inhibiting the viral 
life cycle at different stages. The genes encode proteins that affect viral entry, gene 
transcription and translation, genome replication, and viral assembly (Fensterl, 
Chattopadhyay, & Sen, 2015). Overexpression of the type I IFN response have also been 
associated with autoimmunity (Banchereau & Pascual, 2006).  
 
The Goal of this Thesis 
 The goal of this thesis is to investigate how the conditional knockout of Ikaros in 
peripheral T cells will affect the activation of the type I IFN response gene program in 
mouse and human cells, as the phenotype of cells lacking Ikaros is associated with 
inflammatory diseases and autoimmunity. Our results demonstrate that the lack of Ikaros 
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in CD4+ T cells results in upregulation of the type I IFN-induced gene program. This 
upregulation is not due to environmental cues, as it is localized to the T cells harboring 
the conditional Ikaros knockout. This increase in expression of ISGs also negatively 
impacted the ability of the T cells to be infected with virus. In addition, the Ikaros 
conditional knockout mice showed an increase in the number of T cells expressing the 
monocyte marker CD11b. Jurkat cells, a human leukemia T cell line, in which CRISPR 
was used to generate a knockout of Ikaros (obtained from Dr. Éric Milot at the University 
of Montréal) were then used to determine if this increase in ISG expression carried over 
to human cells. However, the data showed that Ikaros is not definitively knocked out in 
the cell lines used. Taken together, the data demonstrate a role for Ikaros in the repression 
of type I IFN gene programs, which is a key pathway to preventing viral infections, and 
also plays a role in autoimmunity. It is important to translate these findings to in vivo 
mouse models, as well as humans, and define the role of Ikaros in ISG expression in 
both. Several table and figures in this thesis were previously published in Lyon de Ana et 
al. (2019).  
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METHODS 
 
Mutant Mice   
The conditional Ikaros knockout mice, henceforth denoted by Ikflox, were 
produced by Dr. Susan Winandy in conjunction with the Mouse Biology Project located 
at the University of California, Davis. The Cre/loxP system was utilized to create a 
conditional knockout of Ikaros only in mature T-cells. LoxP sites were engineered to 
flank exon 8 and the 3’ untranslated region of the Ikaros gene. These mice were bred with 
another mouse containing a Lck distal promoter Cre transgene acquired from The 
Jackson Laboratory. All mice used in the experiments and for the creation of the Ikflox 
mouse were of the C57BL/6 inbred genetic background. PCR analysis was used to 
determine the genotypes of the mice. Procedures and experiments involving the mutant 
mice were approved by the Boston University Institutional Animal Care and Use 
Committee. 
 
Mouse Dissection and Spleen Extraction 
 Mice were sacrificed using a double kill method of isoflurane followed by 
cervical dislocation. Spleens were removed aseptically and placed in RPMI media (RPMI 
1640 medium [GE Healthcare HyClone], with 10% fetal bovine serum [Atlanta 
Biologicals], 50 μM β-mercaptoethanol) on ice. Spleens were ground using frosted glass 
slides and  filtered through 70 μm filters (FischerScientific) to remove debris. Cells were 
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treated with Red Blood Cell Lysis Buffer (Sants Cruz) and washed twice using the RPMI 
media. Live splenocytes were counted using trypan blue exclusion on a hemocytometer.  
 
CD4+ T cell Purification 
 Splenocytes were resuspended in 1 mL CD4 isolation buffer (500 mL Phosphate 
buffer saline [Fisher], 0.5 g bovine serum albumin [Fisher], and 3 g sodium citrate [EM 
Science]) to achieve a concentration of 108 cells/mL. Cells were pre-blocked using 0.5 
μg/mL Fc-block (α-CD32/α-CD16, Biolegend) and rat serum, for a final dilution of 1:100 
each, on ice for 15 minutes. After this incubation, CD4+ T cells were isolated using the 
Dynabeads® FlowCompTM isolation kit (Invitrogen). Using the kit, αCD4 antibody was 
added to the cells, followed by a brief incubation and wash in isolation buffer. Cells were 
bound to the magnetic beads and isolated by incubation with magnets. Bound cells were 
released from the beads using release buffer. The isolated CD4+ T cells were then 
counted using trypan blue exclusion on a hemocytometer.  
 
IFN-α Activation 
For IFN-α activation, 106 cells per well were placed in complete RPMI (RPMI 
1640 medium [GE Healthcare HyClone], with 10% fetal bovine serum [Hyclone], 50 
U/mL penicillin, 4 mM L-glutamine, 50 μg/mL streptomycin, and 50 μM β-
mercaptoethanol) supplemented with 10 ng/mL IL-7 (Peprotech) in four wells and 
incubated overnight at 37°C with 5% CO2. The next day, IFN-α (Biolegend) was added 
to the wells with final concentrations of 0 U/mL, 100 U/mL, 10 U/mL, and 1 U/mL. Cells 
 12 
 
were incubated at 37°C with 5% CO2 for 4 hours. Following incubation, the cells were 
washed, then fixed in RLT Buffer (QIAGEN) supplemented with β-mercaptoethanol and 
stored at -80°C for RNA extraction. RNA was prepared using the RNeasy Mini-Kit 
(QIAGEN) according to manufacturer’s instructions.  
 
Phospho-STAT1 Phosphoflow Staining 
 Each spleen was divided in half. Half was dissociated using glass slides directly 
into 1.6% paraformaldehyde (Electron Microscopy Sciences). Splenocytes were fixed 
and permeabilized overnight with 100% methanol. The other half of the spleen was 
dissociated using glass slides into RPMI media as described above and cultured in 
complete RPMI. They were plated with 100 U/mL IFN-α and incubated for 30 minutes at 
37°C with 5% CO2. Following the incubation, they were fixed and permeabilized with 
100% methanol as described above. The following day, cells were washed twice with 
staining buffer (PBS, 0.5% BSA, and 0.2% NaN3) to remove the methanol, and each set 
was stained with fluorochrome-conjugated α-phosphoSTAT1 (α-pSTAT1, [BD 
Biosciences]) and α-Ikaros (Biolegend).  
 
Peritoneal Macrophage Isolation 
 Extraction of the peritoneal macrophages from mice was performed aseptically. 
The peritoneal cavity was exposed and washed with 5 mL of PBS warmed to 37°C. The 
cells were spun down and counted using a Z1 Coulter® Particle Counter (Beckman 
Coulter). From them, 105 cells were spun onto a slide using a Cytospin centrifuge. A 
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Diff-Quik staining was performed using the Camco® Stain Pak. The remaining cells were 
fixed in RLT Buffer supplemented with β-mercaptoethanol and stored at -80°C for RNA 
extraction. RNA was prepared using the RNeasy Mini-Kit according to manufacturer’s 
instructions. 
 
VSV-eGFP Viral Infection 
 CD4+ T cells were infected with the rVSV-eGFP virus in conjunction with Dr. 
John Ruedas and Dr. John Connor at the Boston University School of Medicine 
(Whitlow, Connor, & Lyles, 2006). The VSV virus used was engineered to express the 
enhanced green fluorescent protein (EGFP). For the infection, 106 cells were cultured in 1 
mL complete RPMI, half supplemented with 10 ng/mL IL-7, and the other half activated 
with 3 μg/mL αCD3 (Biolegend) and 5 μg/mL αCD28 (Bio X Cell) for 24 hours at 37°C 
with 5% CO2. In a second experiment, some cells were treated with 10 U/mL IFN-α. 
Following all activation, 2.3x108 PFU/mL stock virus was added directly to the cells to 
obtain 107 PFU per well. Cells were incubated at 37°C with 5% CO2 for 24 hours. 
Following incubation, the cells were pelleted and fixed in 200 μL of 4% 
paraformaldehyde for 25 minutes at room temperature. Fixed cells were washed with 
PBS, resuspended in PBS, and analyzed using flow cytometry.  
 
Jurkat T Cells and CRISPR Knockout Cell Lines 
 Jurkat, human leukemia T cells, were obtained from Dr. Andrew Henderson at the 
Boston University School of Medicine. Jurkat CRISPR knockout lines were obtained 
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from Dr. Éric Milot at the University of Montréal. Cas9 clones were generated in Jurkat 
cells using the pCW Cas9 plasmid with puromycin resistance by transfection. Cells 
containing the plasmid were selected using 2 μg/mL puromycin. Expression of Cas9 was 
verified by inducing with 1μM doxycycline for 24 hours, followed by western blot 
analysis. Non-docycycline induced clones were transfected with the plx sgRNA plasmid 
guide with blasticidin resistance that express guide RNAs against IKZF1 5’end 
sequences, which target the sequences to be deleted. The cells were divided in half. One 
half was treated with 2 μg/mL puromycin and 7.5 μg/μL blasticidin as the control, and 
the other half was treated with 2 μg/mL puromycin, 7.5 μg/μL blasticidin, and 1 μM 
doxycyclin (to induce Cas9) to generate an Ikaros knockout cell line. Levels of Ikaros 
protein were monitored by western blot. The clones were: C11-1 Cas9 with guide 1 
against IKZF1, C11-1-6 Cas9 with guide 1 against IKZF1 treated with doxycycline for 
Ikaros knockout, C11-3 Cas9 with guide 3 against IKZF1, and C11-3-17 Cas9 with guide 
3 against IKZF1 treated with doxycycline for Ikaros knockout. CRISPR clones were 
cultured in RPMI media (RPMI 1640 medium [Gibco], with 10% fetal bovine serum 
[Atlanta Biologicals], 50 U/mL penicillin, 4 mM L-glutamine, and 50 μg/mL 
streptomycin) at 37°C with 5% CO2.  
Table 1.  Guide sequences for the CRISPR knockout cell lines. 
CRISPR Clone Sequence 
SgIKZF1-1 5’-GAATGGGGAAGAATGTGCGG-3’ 
SgIKZF1-3 5’-GTAAGCGATACTCCAGATGAG-3’ 
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Flow Cytometry  
 For all stainings, a FACSCalibur (BD Biosciences) flow cytometer was used for 
analysis. Data analyses were conducted on FlowJo V10 software.   
Cell Surface Staining 
 For cell surface staining, 0.5-1x106 cells were pre-blocked using 0.5 mg/mL Fc-
Block (α-CD32/α-CD16) and Rat Serum. Cell surface fluorochrome-conjugated 
antibodies were added to the cells at a concentration of 1:100. Cells were stained with 
fluorochrome-conjugated antibodies against Ly-6C, Ly-6G, CD11b, and T cell receptor 
(Table 1). 
Intracellular Staining 
 For intracellular staining with αIkaros, 0.5-1x106 cells were fixed and 
permeabilized using Intracellular Fixation and Permeabilization Buffer Set (eBioscience). 
Fluorochrome-conjugated antibodies were added to the cells at a concentration of 1:100. 
Table 2.  Antibodies for staining for flow cytometry. 
 
 
Antibody Company Clone Fluorophore 
pSTAT1 BD Biosciences 4a FITC 
CD11b BD Biosciences M1/70 PE, APC 
Ly-6G BD Biosciences 1A8 PE-CyTM7 
Ly-6C BioLegend HK1.4 APC 
Ikaros Biolegend  2A9 PE 
TCR eBioscience UC7-13D5 PE 
 16 
 
Quantitative Real Time PCR (qRT-PCR) 
 cDNA was synthesized using Maxima H Minus Reverse Transcriptase 
(ThermoScientific). qRT-PCR was conducted using SsoAdvanced Universal SYBR® 
Green Supermix (Bio-Rad) on a Bio-Rad MyiQ iCycler. Raw data was obtained on the 
Bio-Rad iQ5 software and analyzed using the Pfaffl method. This method normalized the 
raw data of target genes to a reference gene HPRT. All of the primers used for analysis 
were created by IDT DNA Technologies.  
Table 3.  qRT-PCR primers and their sequences. 
Species  Primer   Sequence 
Mouse HPRT F 5’-GGATATGCCCTTGACTATAATGAG-3’ 
  R 5’-GCCACAGGACTAGAACACC-3’ 
 IK7 F 5’-TCTACCTAACCAACCACATCAAC-3’ 
  R 5’-TGCTGACCACACGGAAGG-3’ 
 Axl F 5’-GGAGGAGCCTGAGGACAAAGC-3’ 
  R 5’-TACAGCATCTTGAAGCCAGAGTAGG-3’ 
 IfitM3 F 5’-CTGCTGCCTGGGCTTCATAG-3’ 
  R 5’-GGATGCTGAGGACCAAGGTG-3’ 
 ifiH1 F 5’-TCCTGGATGTTCTGCGCCAA -3’ 
  R 5’-GACGAGTTAGCCAAGTCTGTGTT-3’ 
 Eif2ak2 F 5’-AAGCAGGAGGCAAGAAACG-3’ 
  R 5’-TGACAATCCACCTTGTTTTCGT-3’ 
 Ifi44 F 5’-AGCCCTATGGAGACCTGGTT-3’ 
  R 5’-AGCTAGACTTCCCAGCTCCA-3’ 
 Parp12 F 5’-CGGATCCAGACCATGGGC-3’ 
  R 5’-GGCATCTCTCGCAAAGTAGC-3’ 
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 Oas2 F 5’-CCCTGTGAAGGAAGTGGCTA-3’ 
  R 5’-CTGTTGGAAGCAGTCCATGA-3’ 
Human HPRT F 5’-GTAGCCCTCTGTGTGCTCAAGG-3’ 
  R 5’-GGCTTATATCCAACACTTCGTGGGG-3’ 
 Ik7 F 5’-AACGTCGCCAAACGTAAGAG-3’ 
  R 5’-CCATCACGTGGGACTTCATCA-3’ 
 Ik5’ C11-1 F 5’-GATGAGCCCATGCCGATCCC-3’ 
  R 5’-CCGCACATTCTTCCCCATTC-3’ 
 Ik5’ C11-3 F 5’-GTAAGCGATACTCCAGATGAG-3' 
  R 5’-TTCATTTCACAGGCACGCCCA-3’ 
 
Statistical Analysis 
 All statistical analyses were conducted on Microsoft Excel using two-tailed 
Student t-tests.  
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RESULTS 
Generation of a conditional knockout of Ikaros in mature T cells 
Ikaros germline knockout mice (Ikaros null mice) have defects in thymocyte 
maturation and develop T cell leukemia that arises in the thymus, making them an 
inappropriate system with which to study the role of Ikaros in mature T cells. To do this, 
an Ikaros floxed (hereby denoted as Ikflox) mouse was generated using the Cre/loxP 
system. It was bred against dLck-Cre transgenic mice to induce the deletion in mature T 
cells. Ikflox mice with no Cre transgene (wild type T cells) are hereafter referred to as Cre- 
and Ikflox mice with a Cre transgene (Ikaros deficient T cells) are hereafter referred to as 
Cre+. qRT-PCR, western blot, and intracellular flow analyses have shown the efficient 
deletion of Ikaros in Cre+ peripheral T cells and not in immature thymocytes. Thymocyte 
and T cell populations in the spleen appear to be normal, and this demonstrates that 
normal T cell development occurs in these mice (Lyon de Ana et al., 2019).  
 
Microarray analysis reveals an upregulation of inflammatory pathways 
 In order to examine how the lack of Ikaros affects CD4+ T cells, microarray was 
performed on freshly isolated CD4+ T cells as well as those that have been activated for 
24 hours with αCD3/αCD28 for both Cre+ and Cre- T cells. The microarray data was 
analyzed using gene-set enrichment analyses (GSEA), which showed that genes 
specifically related to inflammation, autoimmune disease, and interferon pathways were 
upregulated in the Cre+ T cells activated for 24 hours relative to the activated Cre- T cells 
(Table 4).  
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Table 4.  In the absence of Ikaros, expression of pathways linked to inflammation 
and autoimmunity are upregulated in activated CD4+ T cells.  
Results of GSEA analyses of microarray data for Cre+ and Cre- CD4+ T cells activated 
with αCD3/αCD28 for 24 hours. Of the genes analyzed, 1876 gene sets were significantly 
enriched in Cre+ relative to Cre- CD4+ T cells (FDR q < 0.25). Some of the enhanced 
biological processes, functions and pathways are represented (ES: Enrichment score; 
NES: Normalized enrichment score). 
 
Gene Set Name Gene Set Size ES NES 
Nominal 
p value 
FDR q 
value 
Hallmark TNFA Signaling via NFKB 192 0.67 2.72 <0.001 0.0000 
Hallmark IL2 STAT5 signaling 196 0.59 2.41 <0.001 0.0000 
Hallmark Interferon Gamma Response 182 0.59 2.41 <0.001 0.0000 
Hallmark Inflammatory Response 189 0.58 2.37 <0.001 0.0000 
GO Response to Interferon Gamma 104 0.62 2.36 <0.001 0.0000 
Biocarta Cytokine Pathway 18 0.89 2.34 <0.001 0.0000 
KEGG Type I Diabetes Mellitus 31 0.76 2.29 <0.001 0.0001 
Biocarta Inflammatory Pathway 25 0.77 2.20 <0.001 0.0005 
KEGG Graft versus Host Disease 23 0.77 2.21 <0.001 0.0006 
KEGG Allograft Rejection 25 0.77 2.18 <0.001 0.0010 
GO Response to Interferon Beta 20 0.79 2.11 <0.001 0.0022 
Hallmark Interferon Alpha Response 87 0.58 2.08 <0.001 0.0030 
GO Negative Regulation of Viral 
     Genome Replication 35 0.68 2.06 <0.001 0.0037 
KEGG Autoimmune Thyroid Disease 27 0.69 2.02 <0.001 0.0057 
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Table 5.  In the absence of Ikaros,  expression of pathways linked to the response to 
type I IFNs are upregulated in CD4+ T cells. 
Results of GSEA analyses of microarray data for freshly isolated Cre+ and Cre- CD4+ T 
cells. Of the genes analyzed, 152 gene sets were significantly enriched in Cre+ relative to 
Cre- CD4+ T cells (FDR q < 0.25). Some of the enhanced biological processes, functions 
and pathways are represented (ES: Enrichment score; NES: Normalized enrichment 
score). 
 
Gene Set Name Gene Set  Size ES NES 
Nominal  
p value 
FDR q  
value 
Hallmark Interferon Alpha Response 87 0.63 2.23 <0.001 0.0033 
Reactome Interferon Alpha Beta  
     Signaling 39 0.73 2.25 <0.001 0.0055 
GO Response to Type I Interferon 41 0.67 2.14 <0.001 0.0244 
Reactome Interferon Signaling 115 0.55 2.06 <0.001 0.0349 
GO Response to Interferon Alpha 16 0.78 2.04 <0.001 0.0358 
Reactome RIG MDA5 Mediated 
Induction of  
     IFN Alpha Beta Pathway 
53 0.59 1.99 <0.001 0.0541 
GO Response to Interferon Beta 20 0.72 1.94 <0.001 0.0756 
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Interestingly, this upregulation in gene sets included those related to type I IFN signaling. 
The enrichment of genes associated with the type I IFN response seen in activated cells is 
also seen in freshly isolated Cre+ cells relative to Cre- cells (Table 5). The microarray 
revealed that expression of ISGs were upregulated, so the genes that appeared to have the 
highest magnitude of upregulation were further analyzed using qRT-PCR. The 
transcription of ISGs is upregulated in Cre+ CD4+ T cells lacking Ikaros relative to Cre- 
cells, especially for IfitM3, Oas2, Eif2ak2, Parp12, Axl, IfitM2, Mx2, Ifih1, and Ifi44 (Fig. 
3).  
The family of interferon-inducible transmembrane (IFITM) proteins, including 
IFITM2 and IFITM3, prevent viral entry into host cells by preventing the fusion of the 
viral membrane of an enveloped virus with the plasma membrane on the host cell (Li et 
al., 2013). The OAS2 gene encodes the 2’-5’-oligoadenylate synthase 2 protein. This 
family of proteins prevents viral propagation via RNA degradation and induction of cell 
apoptosis. The proteins bind to double stranded viral RNA and activate the latent 
interferon-inducible ribonuclease L (RNase L), causing the degradation of the viral RNA, 
and eventually apoptosis of the infected cell (Hovanessian et al., 1977; Kerr & Brown, 
1978). The Eif2af2 gene encodes RNA-dependent protein kinase (PKR), which inhibit 
viral translation via interaction with viral mRNA (Metz & Esteban, 1972; Friedman et al., 
1972). Interestingly, these proteins also interact with the OAS protein family and the 
RNase L pathway (Hovanessian & Kerr, 1979). The poly(ADP-ribose) polymerase 
(PARP) family of proteins have functions in chromatin remodeling, transcription, and 
cell apoptosis (Hassa & Hottiger, 2008; Schreiber et al., 2006; Gibson & Kraus, 2012).   
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Figure 3.  Ikaros is necessary for supression of ISGs in peripheral T cells. 
(A) Heat map showing comparisons of gene expression of ISGs from a transcriptome 
analysis of freshly isolated Cre+ and Cre- peripheral CD4+ T cells. Contains results from 
three independent expriments. Expression of all genes shown were enhanced by 1.4-fold 
in Cre+. Samples were statistically significant at p ≤ 0.02, and q < 0.25. (B) qRT-PCR 
analyses of expression of ISGs in resting CD4+ T cells normalized to HPRT. Shown are 
the ratios of normalized Cre+ to Cre- values. Error bars represent ±SEM. *p ≤ 0.01, **p 
≤ 0.005 
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PARP12 inhibits viral translation directly by binding to polysomes, the grouping of 
ribosomes translating the viral RNA (Atasheva, Frolova, & Frolov, 2014). Axl is one of 
three TAM (Tyro3, Axl, and Mer) receptors that interacts with TAM ligands on an 
infected apoptotic host cell. Activation of the receptor causes phosphorylation of IFNAR 
receptors and STAT1, which dimerizes and downregulates expression of inflammatory 
genes (Rothlin et al., 2007; Lemke and Rothlin, 2008). Mx2 is a GTP-binding protein 
which acts as an antiviral protein. The mechanism of action of the protein is not fully 
known, though it may act during several stages of the viral life cycle to inhibit its 
propagation (Kane et al., 2013).  The interferon induced with helicase C domain 1 
(IFIH1) protein inhibits viral replication by triggering apoptosis of virally infected cells 
(Yoneyama et al., 2005). Lastly, interferon induced protein 44 (IFI44) prevents viral 
infection by halting the cell life cycle of the host cell infected by the virus. The exact 
mechanism of the protein is unknown (Hallen et al., 2007). 
  
Lack of Ikaros results in enhanced expression of ISGs that mimic a type I IFN 
response  
 The next step was to determine the magnitude of upregulation of ISGs in Cre+ 
CD4+ T cells alongside a genuine type I IFN response. Cre+ and Cre- CD4+ T cells were 
treated with 0 U/mL, 100 U/mL, 10 U/ml, and 1 U/mL of IFN-α for 4 hours, immediately 
followed by RNA isolation. Some of the genes which showed significant upregulation in 
the microarray analysis were analyzed. In all cases, enhanced expression of ISGs was 
seen in Cre+ CD4+ T cells undergoing a type I IFN response relative to Cre- cells.  
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Figure 4.  Lack of Ikaros enhances a type I IFN reponse. 
qRT-PCR analyzes of Cre+ and Cre- peripheral CD4+ T cells stimulated with 0 U/mL, 
100 U/mL, 10 U/mL, and 1 u/mL of IFN-α for 4 hours.  
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Between Cre+ and Cre- CD4+ T cells, significant differences in expression were observed 
for 0 U/mL, 100 U/mL, and 1 U/mL for IfitM3 (p = 0.006, p = 0.035, and p = 0.001, 
respectively) and OAS2 (p = 0.002, p = 0.022, and p = 0.002, respectively), and 0 U/mL 
and 1 U/mL for Parp12 (p = 0.008 and p = 0.002, respectively). No significant difference 
was noticed in the 10 U/mL samples for IfitM3 (p = 0.071), OAS2 (p = 0.086), and 
Parp12 (p = 0.096), as well as for 100 U/mL for Parp12 (p = 0.139) (Fig. 4).  
 Interestingly, in some cases, levels of expression of the ISG in the untreated Cre+ 
CD4+ T cells are comparable to those observed in Cre- CD4+ T cells stimulated with IFN-
α. There was no significant difference in expression between 0 U/mL Cre+ cells and 100 
U/mL Cre- cells for IfitM3 (p = 0.794), and between 0 U/mL Cre+ cells and 10 U/mL 
Cre- cells for OAS2 and Parp12 (p = 0.966 and p = 0.429, respectively) (Fig. 4). Taken 
together, this shows that the magnitude of ISG expression in the Cre+ CD4+ T cells is 
similar to that observed during a bona fide IFN-α response in Cre- cells.  
 
Increased expression of ISGs is not due to an inflammatory environment 
Next, we wanted to determine if the upregulation of ISGs is due to the presence of 
an inflammatory environment in the mouse. This was done in two separate experiments. 
The purpose of the first experiment was to determine whether p-STAT1 is present in 
Cre+ cells using flow cytometry. P-STAT1 is a downstream activator of both the type I 
and type II IFN responses. 
 26 
 
 
Figure 5.  IFNAR1 signaling pathways are not activated in freshly isolated Cre+ 
splenocytes. 
Flow cytometry plots showing the expression of Ikaros and p-STAT1 in freshly isolated 
and IFN-α activated Cre+ and Cre- splenocytes. Cells treated with IFN-α served as the 
positive control for the presence of pSTAT1. As found in previous studies, T cells within 
the Cre+ splenocytes fall within the Ikaros negative quadrants.  
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Half of the spleens were dissociated and fixed immediately after extraction as the 
activation of STAT1 in the pathway is brief. The other half of the spleen was dissociated 
and treated with IFN-α as a positive control. Cells were stained with αIkaros in addition 
to αp-STAT1 to identify the T cells, which would be Ikaros negative. P-STAT1 was 
present in the IFN-α activated cells; however, no p-STAT1 was present in the splenocytes 
fixed immediately after isolation (Fig. 3).  
The second experiment was to analyze the expression of ISGs in macrophages. A 
DiffQuik staining was done for visual analysis of the cell populations. Peritoneal 
macrophages are present in both the Cre+ and Cre- mice, and visually appear to be 
normal (Fig. 6A). In addition to the DiffQuik, qRT-PCR analysis was done to analyze 
ISG expression in the Cre+ and Cre- cells, as these macrophages should not contain the 
Ikaros deletion. Therefore, any change in ISG expression in a peritoneal macrophage 
would be due to environmental changes in the mouse. Expression of ISGs were very 
similar between Cre+ and Cre- cells (Fig. 6B). Taken together, these data show that the 
upregulation of ISG expression in freshly isolated Cre+ CD4+ T cells is not due to an 
inflammatory environment in the mouse. Otherwise, it is likely that ISG expression in 
macrophages would have been affected and the IFNAR1 pathway activated. 
   
Analysis of myeloid cell populations in Cre+ mice  
 As part of the analysis of leukocyte populations in the Cre+ mice, we examined 
populations of monocytes and neutrophils in the spleens. 
 
 28 
 
 
Figure 6.  Peritoneal macrophages showed no significant increase in ISG expression. 
Peritoneal macrophages were collected from the peritoneal cavities of Cre+ and Cre- 
mice, counted, and stained. (A) Cells were stained using the Diff-Quik. (B) Cells were 
immediately fixed and RNA was extracted for qRT analysis.  
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Splenocytes were isolated and stained with fluorochrome-conjugated antibodies against 
CD11b, Ly-6C, and Ly-6G. CD11b is a cell surface receptor expressed predominantly on 
myeloid cells, CD11b and Ly-6C double positive, Ly-6G- (CD11b+Ly-6C+Ly-6G-) 
expression is specific to monocytes, and CD11b, Ly-6C, and Ly-6G triple positive 
(CD11b+Ly-6C+Ly-6G+) expression is specific to neutrophils (Buechlar et al., 2013). 
After analyzing flow results, it was concluded that the amounts of monocytes differ 
between the Cre+ and the Cre- mouse spleens (Fig. 7 and data not shown).  In Cre+ mice, 
the percentage of monocytes in the spleen increases, while the percentage of neutrophils 
was unchanged compared to Cre- (Fig. 7). 
 To confirm that this was indeed an increase in monocytes, a second staining was 
done using fluorochrome-conjugated antibodies for CD11b, Ikaros, and T cell receptor 
(TCR). TCR is exclusively expressed on the surface of T cells. There was an expression 
of CD11b+TCR+ cells in the spleens of Cre+ mice, whereas percentages of myeloid 
cells, which would be CD11b+TCR-, are equivalent. This indicates that the cells 
originally taken to be monocytes are indeed CD11b+ T cells. Taken together, this 
indicates that the increase in cell percentage in the spleen is of CD11b+ T cells (Fig. 8, 
Ikaros staining not shown). 
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Figure 7.  There appears to be an increase in monocytes in the spleen in Cre+ mice. 
Splenocytes stained with fluorochrome-conjugated antibodies CD11b, Ly-6C, and Ly-6G 
and analyzed using flow cytometry. Cells that were double positive for CD11b and Ly-
6C were bracketed and separated into Ly-6G negative and positive populations to identify 
monocytes and neutrophils, respectively.  
 
 
  
 31 
 
 
Figure 8.  The increase in cells is in T cell, not monocyte, populations.  
Splenocytes were isolated and stained with fluorochrome-conjugated antibodies TCR and 
CD11b and analyzed using flow cytometry. 
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The increase of ISG expression decreases the ability of Cre+ CD4+ T cells to become 
infected with a virus 
 The type I IFN response occurs in the presence of a viral infection in cells. It 
would be expected that the increase of expression of ISGs would decrease the ability of 
the cell containing the Ikaros deletion to be infected with a virus. To analyze this, freshly 
isolated Cre+ and Cre- CD4+ T cells were 1) treated with IL-7, 2) activated with 
αCD3/αCD28, or 3) activated with αCD3/αCD28 and treated with 10 U/mL IFN-α. In all 
cases, this was followed by an infection with VSV-eGFP for 24 hours. Infection 
efficiency was measured by percentage of cells expressing GFP as analyzed by flow 
cytometry. Cre+ and Cre- CD4+ T cells stimulated with IL-7 were not efficiently infected 
with the virus (Fig. 9A). When activated, Cre+ CD4+ T cells did not infect with VSV-
eGFP as well as Cre- T cells (p = 0.0016). Cells treated with IFN-α showed lower levels 
of infection with the virus, as expected for a positive control (p = 0.011 and p = 0.00125 
for Cre+ and Cre- cells, respectively) (Fig. 9B, Fig. 10). Interestingly, the infection levels 
of Cre+ cells not treated with IFN-α were comparable to those of Cre- cells treated with 
IFN-α, suggesting that the level of upregulation of ISG expression is similar to that of 
cells undergoing the induction of the type I IFN gene program (p = 0.2615) (Fig. 9B, Fig. 
10). 
 
Analysis of two new Ikaros CRISPR knockout human T cell lines  
 The next step in investigating the role of Ikaros in repressing ISG expression was 
to determine if this role translates to human T cells.  
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Figure 9.  Cre+ CD4+ T cells have a decreased ability to be infected by virus. 
Flow cytometry plots of cells were infected with a GFP-expressing virus. (A) Freshly 
isolated Cre+ and Cre- CD4+ T cells were treated with IL-7 overnight and infected with 
VSV-eGFP. (B) Freshly isolated Cre+ and Cre- CD4+ T cells were activated with 
αCD3/αCD28 with or without 10 U/mL of IFN-α overnight, followed by infection of 
VSV-eGFP. Shown are the results from one of two independent experiments.  
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Figure 10.  The percent of Cre+ CD4+ T cells infected with virus is comparable to 
Cre- CD4+ T cells stimulated with IFN-α.  
Bar graphs show a compilation of data from two independent VSV-eGFP infection 
experiments performed in duplicate. IFN-α treatment caused a significant decrease in the 
percent of cells infected with virus for both Cre+ and Cre- cells compared to those not 
stimulated with IFN-α (p = 0.011 and p = 0.00125, respectively). There was a significant 
difference between the percent infected between Cre+ and Cre- cells not stimulated with 
IFN-α (p = 0.0016). There was no significant difference between Cre+ cells not 
stimulated with IFN-α and Cre- cells stimulated with IFN-α (p = 0.2615).  
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Jurkat cells, human leukemia T cell lines, containing a knockout for Ikaros via the 
CRISPR/Cas9 system were obtained from Dr. Éric Milot at the University of Montréal. 
Guide RNAs were used to induce deletion of the 5’ end of the Ikaros gene (Ikzf1), either 
in exon 1/2 or exon 3 for the C11-1-6 or C11-3-17 cells lines, respectively. In theory, the 
mutations would cause a deletion in the gene that would prevent it from being 
transcribed. To test this, qRT-PCR primers were used that amplified exon 8 (encoded for 
at the 3’ end of the gene) for both cell lines, as well as for exons 1/2 and 3 for the C11-1 
and C11-3 cell lines, respectively, in the region (5’ end) targeted for the CRISPR 
mutation.  
There is no decrease in levels of exon 8 in C11-1-6 containing the knockout, 
compared to the C11-1 control line. However, there appears to be a knockdown in levels 
of exon 1/2 (Fig. 11A). For the C11-3 cell line, a decrease in levels of exon 8 can be seen 
in the mutant C11-3-17 cell line compared to the control C11-3 cell line. The levels of 
exon 8 are higher than that of normal Jurkat cells containing no control plasmids or 
mutations. In addition, there appears to be no decrease in levels of exon 1/2 in the mutant 
C11-3-17 compared to the C11-3 control line (Fig. 11B). Taken together, these results 
show that transcription of Ikzf1 is not completely knocked out in these cell lines.   
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Figure 11.  Knockout of Ikzf1 expression is not seen at the transcriptional level.  
Jurkat cells, as well as C11-1, C11-1-6, C11-3, and C11-3-17 cell lines were analyzed for 
expression of Ikzf1 by qRT-PCR. For all of the cells, transcription of exon 8 were 
analyzed. (A) For C11-1 and C11-1-6, levels of exon 1/2 were analyzed using primers for 
the sequence targeted by the CRISPR/Cas9 system for this cell line. (B) For C11-3 and 
C11-3-17, levels of exon 3 were analyzed using primers for the sequence targeted by the 
CRISPR/Cas9 system for this cell line 
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DISCUSSION 
 
 Ikaros is a critical factor in the regulation of development and maturation of 
hematopoietic stem cells (Nichogiannopoulou et al., 1998). Previous studies have shown 
that Ikaros plays a critical role in the differentiation of CD4+ T cells into the different 
helper T cell subsets as well, with T cells completely lacking the ability to differentiate 
into the Th2 or Th17 subsets in Ikaros null mice (Quirion et al., 2009; Wong, Hatfield, & 
Brown, 2013). However, Ikaros is necessary for the proper maturation of lymphoid 
progenitors into T cells. Therefore, in order to study the role of Ikaros in mature CD4+ T 
cells, it was necessary to develop a model in which Ikaros would be conditionally 
knocked out in T cells after they had matured. This model utilizes the Cre/loxP system 
and a Cre transgene expressed from the distal Lck Cre promoter, which is expressed in 
mature T cells only. We used these mice (called Cre+ mice) to define a role for Ikaros in 
the type I interferon (IFN) response, and subsequently, the gene programs affected by this 
response (Lyon de Ana et al., 2019). 
 A global gene analysis using microarrays was used as a preliminary approach to 
define how the lack of Ikaros affects gene expression in the Cre+ CD4+ T cells. This 
approach was used on CD4+ T cells from the spleen, which included a mix of naïve cells, 
memory cells, T cells differentiated into subsets, and regulatory T cells (Tregs). This was 
because it is possible that, with the Ikaros mutation, cells may have altered or a lack of 
expression of cell surface receptors, which would impact the results of cell sorting. 
Through gene-set enrichment analysis (GSEA) of the microarray data, it was observed 
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that the genes whose expression were most different between Cre+ and Cre- phenotypes 
were those associated with the type I IFN response gene program. This over-expression 
of type I interferon (IFN) response gene pathways was seen in Cre+ CD4+ T cells 
activated with αCD3/αCD28, as well as freshly isolated/resting cells. Overexpression in 
resting Ikaros-deficient cells suggests that Ikaros functions as a repressor of these gene 
programs in the absence of an inflammatory signal. Interestingly, it was also observed 
that, in some cases, the upregulation of interferon sensitive genes (ISGs) in Cre+ T cells 
was comparable to that seen in Cre- cells treated with IFN-α, indicating that the 
magnitude of overexpression of the ISGs in Cre+ cells approximated that observed during 
a bona fide type I IFN response.  
So, is this response a direct product of the Ikaros knockout mutation in the T cells, 
or is there an inflammatory environment in the mutant mouse that could be driving this 
upregulation in ISGs? To test this, we conducted two different experiments. In the first 
experiment, splenocytes were immediately dissociated and fixed before being stained 
with αIkaros (to identify T cells) and αp-STAT1 (activated by IFN-α signaling), followed 
by flow cytometry analyses. They were fixed immediately, as the phosphorylation of 
STAT1 is temporary and short-lived. The results revealed that STAT1 is not 
phosphorylated in freshly isolated Cre+ cells, showing that IFN-α signaling is not active 
in these cells. The second experiment was done to analyze the expression of ISGs in 
peritoneal macrophages, which would have Ikaros. The macrophages were immediately 
fixed and the RNA extracted. qRT-PCR analysis revealed that the ISGs most 
overexpressed in the CD4+ T cells lacking Ikaros were expressed at levels in the Cre+ 
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macrophages comparable to those in the Cre- macrophages. Taken together, these data 
show that the upregulation in ISGs in the Cre+ CD4+ T cells is due to the Ikaros 
mutation, rather than an inflammatory environment in the mouse. Since the type I IFN 
response is associated with viral infections, we infected CD4+ T cells with a virus 
containing GFP. Flow cytometry analysis revealed that Cre+ CD4+ T cells did not infect 
with the virus as well as the Cre- cells, as expected. 
Why might this upregulation in ISGs be significant? Studies have shown that the 
type I IFN response both enhances and restrains proinflammatory pathways. A study of 
B-cell tolerance in systemic lupus erythematosus (SLE) patients revealed that there is a 
link between the overactivation of type I IFNs and the proinflammatory response in B 
cells (Liu et al., 2018). Conflicting information was revealed by Rothlin et al. (2007) as 
well as by Lemke and Rothlin (2008) that TAM receptors, one of which is the protein 
Axl encoded by the ISG Axl, act to suppress transcription of proinflammatory genes. 
Therefore, this proinflammatory phenotype of Ikaros deficient CD4+ T cells, defined by 
their overexpression of inflammatory cytokines when activated, should be investigated 
further, as this upregulation of type I ISGs could be linked to proinflammatory 
environments that lead to autoimmunity.   
 It is possible that overexpression of ISGs is due to some kind of epigenetic 
change or altered post-translational modification (PTM) in Ikaros deficient CD4+ T 
cells. It is becoming well known that PTM and epigenetic modifications play a role in 
the healthy or pathologic expression of type I IFNs. In one study focusing on antiviral 
immunity, DNA methyltransferase Dnmt3a indirectly increased expression of type I IFNs 
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via histone deacetylase HDAC9. Dnmt3a has the ability to bind directly to DNA, as well 
as to methylate DNA, to activate transcription and silence expression, respectively. Upon 
infection with a virus, Dnmt3a bound directly to the promoters of Hdac9, upregulating 
transcription of the gene. The protein HDAC9 then deacetylated the molecule TANK-
binding kinase 1 (TBK1), which is critical for the activation of transcription factor IRF3. 
This study revealed the crosstalk between epigenetic modifications and PTMs to maintain 
a type I IFN response (Li et al., 2016). Interestingly, another study revealed that Ikaros is 
a regulator of epigenetic modification. Song et al. (2016) showed in a study analyzing the 
effect of Ikaros binding on chromatin structure in acute lymphoblastic leukemia that 
Ikaros binding to chromatin was associated with histone modifications, specifically with 
methylation and acetylation. Knowing that the type I IFN response is controlled in part 
by epigenetic modification, and that Ikaros has chromatin remodeling abilities, the next 
step would be to analyze the chromatin structure and histone modifications of the ISGs in 
mutant CD4+ T cells lacking Ikaros compared to wild type cells that express Ikaros to 
determine if Ikaros plays a role in maintaining chromatin structure to regulate expression 
of ISGs. 
 In the analysis of myeloid cells in the mutant mice, we stained splenocytes with 
antibodies against CD11b, Ly-6C, and Ly-6G and analyzed them using flow cytometry. 
The initial analysis revealed an increase in the percentage of CD11b+ cells, which we 
assumed to be monocytes, in the spleens of Cre+ mutant mice. A second staining with 
antibodies against TCR, CD11b, and Ikaros revealed that the increase was actually in 
CD11b+ T cells in the mutant mice, rather than monocytes. CD11b expression is 
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important for the identification and isolation of neutrophils and monocytes during 
inflammation (Jutila et al., 1990, p. 227-235). However, a small population of CD8+ T 
cells express CD11b, which include virus-specific cytotoxic T lymphocytes (CTL) and 
virus-specific memory CTLs. Upon infection with a virus, the population of 
CD8+CD11b+ T cells increases during the peak of the infection (McFarland et al., 1992). 
This was confirmed in another study, in which patients suffering from acute viral 
infections showed a 3-fold increase in the percentage of CD11b+ CTLs, which decreased 
to normal levels upon eradication of the infection (Fiorentini et al., 2001). We have 
already shown that the upregulation of ISGs in CD4+ T cells is not due to an 
inflammatory environment, and we know that the CD11b+ T cells in mutant mice are not 
activated or memory cells (data not shown). The identity of this expanded population of 
CD11b+ T cells remains to be explored. However, given that Ikaros deficient cells show a 
deregulation in the type I IFN gene program, and CD8+CD11b+ CTLs are virus-specific, 
this relationship should be examined further by analyzing the expression of Ikaros and 
ISGs in CD8+CD11b+ CTLs in these mutant mice.  
 We observed deregulation of the type I IFN gene programs in Ikaros-deficient 
CD4+ T cells in mice, and so we proceeded to analyze this in Jurkats, a human leukemia 
T cell line, containing a knockout for Ikaros via the CRISPR/Cas9 system. The two cell 
lines were obtained from Dr. Éric Milot from the University of Montréal. In theory, the 
mutation would cause a deletion in the Ikzf1 gene that prevented transcription. Before 
beginning our studies, we decided to test if this was true. Using qRT-PCR analysis, we 
used primers within exon 8 to amplify the 3’ end of Ikzf1, as well as primers to amplify 
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the region containing the CRISPR mutation, which was within the 5’ end of Ikzf1 for both 
cell lines. We did not observe a definitive knockout of Ikaros expression at the level of 
mRNA in these cell lines. However, a western blot provided by Dr. Milot showed 
knockdown of the protein. These conflicting results could indicate one of two things: 
either Dr. Milot has successfully knocked out Ikaros, or a mutant form of the protein is 
being transcribed and translated, which cannot be identified by the antibody he is using 
for the western blot. The former is possible because, even though there is some 
transcription of the CRISPR edited Ikaros gene, it is possible that no stable protein is 
formed during translation, and so the knockout is successful. The latter is also possible, 
as several isoforms of the Ikaros protein do not contain certain exons, such as exons 1/2 
and 3 which were the exons targeted for the mutation, since they can be removed during 
alternative splicing. It is possible that, even if the introduction of mutations in these exons 
is successful, the mutant exons are being spliced after transcription, and altered isoforms 
of the protein are still expressed. More should be done with these cell lines to determine 
which of these possibilities is true.  
Other methods could be utilized to create this knockout of Ikaros in Jurkats as 
well, such as RNA interference (RNAi) by short hairpin RNA (shRNA). The shRNAs 
can be cloned into a plasmid from which they can be expressed, and delivered to cells via 
viral or non-viral vectors. Once in the cell, the shRNA is transcribed by polymerase III. 
The transcripts are modified by the endoribonuclease DICER into small interfering RNAs 
(siRNA). The siRNAs then interact with the RNA-induced silencing complex (RISC) and 
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guide the complex to the target for degradation, causing a knockdown of the target 
(Machitani et al., 2016).   
This method, while useful, does bring with it some problems. The introduction of 
shRNAs into mammalian cells induces the type I IFN response (Machitani et al., 2016). 
Since our goal is to use the system to define a role for Ikaros in repressing ISGs in human 
cells, this is problematic. If this method is used to attempt to induce an Ikaros mutation in 
Jurkats, there would be no way to determine if any observed upregulation of ISG 
expression was due to a lack of Ikaros, or because of the introduction of shRNA to the 
cell.  
In conclusion, we have shown that CD4+ T cells lacking Ikaros express a 
proinflammatory phenotype and an upregulation in expression of ISGs. These data 
suggest that Ikaros plays a role as a repressor of type I IFN gene programs. We also 
showed that in the absence of Ikaros there was an increased population of CD11b+ T 
cells, which may be related to this proinflammatory nature of the cells. Lastly, we were 
unable to test this role in human T cells, as the knockout of Ikaros could not be confirmed 
in the CRISPR/Cas9 Jurkat cell lines. The next step would be to develop an Ikaros 
deficient model in human T cells to determine if the role of Ikaros in repression of ISGs 
shown in this thesis translates.  
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Lack of Ikaros Deregulates Inflammatory Gene Programs in
T Cells
Carolina Lyon de Ana, Ksenia Arakcheeva,1 Parul Agnihotri,1,2 Nicole Derosia, and
Susan Winandy
CD4 Th cells are organizers of the immune response, directing other immune cells to initiate and maintain effective humoral and
cellular immunity. CD4 T cells differentiate into distinct Th effector or regulatory subsets in response to signals delivered to them
during the course of infection. Ikaros is a transcription factor that is expressed in blood cells from the level of the hematopoietic stem
cell. It is required for normal thymic T cell development and serves as a tumor suppressor, as lack of Ikaros in developing lymphoid
cells results in leukemia. To study the role of Ikaros in CD4 T cell differentiation and function, an Ikaros conditional knockout mouse
was developed such that Ikaros expression was deleted specifically in mature T cells, thus avoiding defects observed in germline
Ikaros mutant mice. Using this model system, we have shown that in the absence of Ikaros, CD4 T cells are able to attain Th1, Th2,
and Th17, but not inducible regulatory T, cell fates. However, they show enhanced expression of a cohort of proinflammatory
cytokines, resulting in differentiation of Th17 cells with a phenotype that has been associated with autoimmunity and pathological
inflammation. In addition, we define Ikaros as a repressor of the gene program associated with the response to type I IFNs, another
key pathway whose deregulation is linked to autoimmunity. Taken together, these data definitively define Ikaros as a critical reg-
ulator at the center of the inflammatory response in T cells and highlight a potential role in suppressing autoimmunity. The
Journal of Immunology, 2019, 202: 1112–1123.
C D4 T cells are required for elicitation of effective humoraland cellular immunity. Naive CD4 T cells have uniformdifferentiation potential, and it is the nature of a pathogenic
assault that elicits signals to drive acquisition of specific Th cell
phenotypes tailored to combat the infection. CD4 T cells can also
attain an inducible regulatory T (iTreg) cell phenotype, which plays a
role in downregulation of the immune response to prevent dangerous
inflammation. Cytokines, together with signals delivered through TCR
complex and coreceptor, deliver the key instructive signals that drive
the Th or iTreg cell lineage decision by, ultimately, changing programs
of gene expression. Deregulation of the response to these cues can lead
to autoimmunity and inflammatory diseases.
Ikaros is a highly conserved nuclear protein (.95% at the amino
acid level between mice and humans) that is expressed at high
levels in CD4 Th cells, as well as in all blood cell lineages from
the level of the hematopoietic stem cell (HSC) (1, 2). In humans,
variants in the Ikaros gene sequence have been linked to inflam-
matory and autoimmune diseases including asthma (3), systemic
lupus erythematosus (4, 5), type 1 diabetes (6, 7), Crohn disease
(8), and systemic sclerosis (9). Its role in these diseases is un-
known. Mice with a germline knockout mutation in the Ikaros
gene (Ikaros null mice) display defects in HSC function as well as
in development and/or function of all blood cell lineages studied
to date (10–16). Studies using T cells from mice with germline
mutations in the Ikaros gene have suggested that Ikaros is required
for multiple aspects of CD4 Th cell development and function. In
particular, they support a role for Ikaros in 1) the Th1 versus Th2
fate decision, whereby Ikaros null T cells cannot attain the Th2 but
default to the Th1 fate (17); 2) differentiation of Th17 and iTreg
cells, whereby differentiation of both is significantly decreased in
the absence of Ikaros (18, 19); and 3) regulation of T cell pro-
liferation whereby Ikaros-deficient T cells display increased levels
of proliferation and altered cell cycle kinetics, with a shorter time
frame to entry into S phase (20). Although these studies provide
evidence that Ikaros is an important regulator of CD4 T cell dif-
ferentiation and function, it has been argued that use of Ikaros
germline mutant models for these studies is contraindicated. This
is due to the fact that Ikaros plays a critical role in regulating early
T cell maturation processes that take place in the thymus. Spe-
cifically, lack of Ikaros results in greatly reduced numbers of
thymocytes because of an impaired ability of progenitor cells to
commit to the lymphoid lineage as well as defects in both positive
and negative selection (14, 15, 21, 22). Adding yet another layer
of complication, the germline Ikaros mutant mice that have been
used to study Ikaros function in mature T cells develop T cell
leukemia that arises in the thymus (15, 23, 24).
Taken together, these phenotypes have led to concerns that
Ikaros null “mature T cells” represent a population of cells that
are so abnormal that they cannot be compared in function or
differentiation potential to wild-type T cells.
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Therefore, to define the function of Ikaros in CD4 T cells, we
have generated an Ikaros conditional knockout (Ikflox) mouse and
used it to delete Ikaros expression specifically in mature T cells.
This would allow T cell commitment and thymic T cell maturation
to occur with intact Ikaros expression. Using these mice, we have
shown that in the absence of Ikaros, mature CD4 T cells are able
to attain Th1, Th2 and Th17, but not iTreg, cell fates. However,
they show enhanced expression of a cohort of proinflammatory
cytokines. This results in differentiation of Th17 cells with a
phenotype that has been associated with autoimmunity and path-
ological inflammation, suggesting that Ikaros acts as a suppressor
of this phenotype. We also show that, in contrast to what has been
demonstrated using T cells from germline Ikaros mutant mice,
lack of Ikaros starting at the level of the mature T cell results in their
reduced ability to proliferate when activated via TCR/coreceptor
pathways. Finally, using genome-wide transcriptomics analyses, we
reveal that in resting CD4 T cells, Ikaros is a repressor of the gene
program associated with the response to type I IFN. Taken together,
these data define Ikaros as a cell-intrinsic regulator of the inflam-
matory response in mature T cells.
Materials and Methods
Mice
The Ikflox mouse was generated in conjunction with the Mouse Biology
Program at University of California, Davis. The Lck distal promoter Cre
transgenic mouse (dLck-hcre3779) was obtained from The Jackson Labo-
ratory. All mice were on the C57BL/6 inbred genetic background. Geno-
types were determined by PCR analyses. Both male and female animals
were used for experiments with no discernable difference in phenotype. All
animal procedures were approved by the Boston University Institutional
Animal Care and Use Committee.
Western blot analyses
Protein extracts were prepared from purified splenic CD4 T cells by cell
lysis with 420 mM NaCl lysis buffer (20 mM Tris-HCl [pH 7.5], 420 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40). Ten micrograms of protein extract
were denatured and electrophoresed on 10% SDS–polyacrylamide gels,
followed by transfer to PVDF membranes. Membranes were probed with
anti-Ikaros (clone 4E9; gift from K. Georgopoulos) followed by, after
stripping of the membrane, anti-Nucleolin (A300-711; Bethyl Laboratories).
In both cases, membranes were incubated with HRP-conjugated secondary
Ab after primary Ab incubation. SuperSignal West Femto (Thermo Fisher
Scientific) was used to visualize HRP-conjugated Abs. Light signal was
detected with a Bio-Rad Universal Hood II and Molecular Imager ChemiDoc
XRS+ Camera (Bio-Rad). Densitometry analyses were performed using
ImageJ software.
Thymocyte and splenocyte preparation
Thymuses or spleens from 6- to 8-wk-old mice were dissected using aseptic
techniques and placed in a petri dish on ice with complete RPMI (RPMI
1640 medium supplemented with 10% FBS, 50 mM 2-ME, 4 mM
L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin). They were
then ground between two glass slides, and red cells were lysed with RBC
lysis buffer (Santa Cruz Biotechnology). After two series of washes with
complete RPMI, cells were counted on a hemocytometer using trypan blue
exclusion to identify live cells.
T cell cultures
Differentiation assays. CD4 T cells were purified from splenocytes using the
Dynabeads FlowComp isolation kit (Invitrogen) according to the manufac-
turer’s instructions. Purified CD4+ cells were plated with 3 mg/ml plate-
bound anti-CD3ε (145-2C11; BioLegend) and 5 mg/ml soluble anti-CD28
(37.51; Bio X Cell) in complete RPMI. For differentiation the following
were added: 1 ng/ml IL-12 (PeproTech) and 5 mg/ml anti–IL-4 (eBioscience)
for Th1; 10 ng/ml IL-4 (PeproTech) and 5 mg/ml anti–IFN-g (BioLegend)
for Th2; 2 ng/ml TGF-b (BioLegend), 50 U/ml IL-2 (PeproTech), 5 mg/ml
anti–IFN-g, and 5 mg/ml anti–IL-4 for iTreg cells; and 1 ng/ml TGF-b,
20 ng/ml IL-6 (PeproTech), 5 mg/ml anti–IFN-g, and 5 mg/ml anti–IL-4 for
Th17. Cells were restimulated with 20 ng/ml PMA and 400 ng/ml ion-
omycin, or plate-bound anti-CD3ε prior to intracellular cytokine staining
or preparation of RNA. When cells were used for intracellular cytokine
staining, they were also incubated with 1 mg/ml brefeldin A (eBioscience)
for 4 h following an initial 2 h of restimulation.
Proliferation and cell cycle analyses. Splenocytes were loaded with 5 mM
CFSE and cultured with 0.5–8 mg/ml plate-bound anti-CD3ε and 5 mg/ml
soluble anti-CD28. Prior to flow analyses, cells were stained with Abs
against CD4 (RM4-5; eBioscience) and CD8 (53-6.7; eBioscience) to
identify T cells. For cell cycle analyses, CD4 T cells were purified from
spleens and plated with anti-CD3ε/anti-CD28 as described above. In some
experiments, 40 mM of the caspase-3 inhibitor Z-DEVD-FMK (ApexBio)
was added to the culture. At 24, 48, and 72 h, cells were harvested, fixed
with 70% ethanol, and stored overnight at 220˚C. Staining was performed
using a solution composed of 50 mg/ml propidium iodide, 3.8 mM sodium
citrate, and 10 mg/ml RNase A.
IFN-a treatment. CD4 T cells were purified from the spleen as described
above followed by incubation overnight with 10 ng/ml IL-7. The next day,
cells were treated with 0, 1, 10, or 100 U/ml IFN-a (BioLegend) for 4 h,
followed by preparation of RNA.
Staining cells for flow cytometry
In all cases, cells were analyzed by flow cytometry after staining on the BD
FACSCalibur (BD Biosciences). Data were analyzed using FlowJo V10
software.
Surface marker staining. Cells were incubated with 2 mg/ml Fc block (anti-
CD32/anti-CD16; BioLegend) and rat serum, followed by staining with the
following fluorochrome-conjugated Abs (Abs from BioLegend or eBioscience
unless otherwise stated): anti-CD8 (53-6.7), -CD4 (RM4-5), -CD11b (M1/70),
-CD44 (IM7), -B220 (RA3-6B2), -CD62L (MEL-14), –Gr-1 (RB6-8C5),
-IgM (II/41), -TCRb (H57-597).
Intracellular staining. For cytokines, cells were fixed and permeabilized
using the Intracellular Fixation & Permeabilization Buffer Set (eBio-
science), followed by staining with fluorochrome-conjugated Abs against
IFN-g (XMG1.2) and IL-4 (11B11). For nuclear protein, cells were fixed
and permeabilized using the Foxp3/Transcription Factor Staining Buffer
Set (eBioscience), followed by staining with fluorochrome-conjugated Abs
against T-bet (eBio4B10), Foxp3 (FJK-16s), GATA3 (TWAJ), RORgt
(B2D), and Ikaros (2A9). For anti–phospho-STAT1 analyses, each spleen
was divided in half. Half was dissociated directly in 1.6% paraformalde-
hyde (Electron Microscopy Sciences), followed by permeabilization with
100% methanol overnight. The other half was prepared for culturing as
described above. Splenocytes were plated with 100 U/ml IFN-a for 30 min
in a tissue culture incubator. They were then fixed and permeabilized with
100% methanol as described above. The next day, both sets of cells were
stained with fluorochrome-conjugated Abs against phospho-STAT1 (clone
4a; BD Biosciences) and Ikaros (2A9).
RNA isolation and quantitative real-time RT-PCR analyses
Total RNAwas isolated from cells using the SV Total RNA Isolation System
(Promega) or RNeasy MiniKit (Qiagen). cDNA was generated with Super-
script Reverse Transcriptase (Invitrogen). Quantitative real-time RT-PCR
(qRT-PCR) was performed using SSOAdvanced Universal SYBR Green
Supermix (Bio-Rad) on a Bio-RadMyiQ Real-Time PCR machine. Raw data
obtainedwas analyzed using the Pfafflmethod to normalize target gene data to
that obtained with primers for the reference gene, HPRT. Primers were
generated by Integrated DNA Technologies. Sequences are available upon
request.
Virus infection
Splenic CD4 T cells were purified and plated with anti-CD3ε/anti-CD28 as
described above. After 16 h, cells were infected with rVSV-eGFP (25) at a
multiplicity of infection of 10 for 24 h. Following infection, cells were
fixed with 4% paraformaldehyde, washed, and analyzed by flow cytometry.
Microarray analyses
Microarray experiments and their subsequent analyses were performed at
the Boston University Microarray Core Facility. Biotin labeling was per-
formed using the WT PLUS Reagent Kit (Affymetrix) according to the
manufacturer’s instructions. The labeled, fragmented DNAwas hybridized
to the Affymetrix Mouse Gene 2.0 ST Array for 18 h in a GeneChip
Hybridization Oven 640 at 45˚C, followed by staining using an Affymetrix
Fluidics Station 450. After staining, microarrays were immediately scan-
ned using an Affymetrix GeneArray Scanner 3000 7G Plus. Microarray
analyses were performed using the R environment for statistical computing
(version 2.15.1). The raw expression data were quality assessed and sub-
jected to background adjustment and normalization. Differential expres-
sion was assessed using the moderated (empirical Bayesian) ANOVA and
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t test implemented in the limma package (version 3.14.4). Nominal
p values were corrected for multiple hypothesis testing using the Ben-
jamini–Hochberg procedure to generate false discovery rate (FDR)–
corrected p values (q values). FDR q , 0.25 are considered significant.
Gene-set enrichment analyses (GSEA) (default parameters with random
seed 1234) were performed using the Entrez Gene versions of the Hall-
mark, BioCarta, Kyoto Encyclopedia of Genes and Genomes (KEGG),
Reactome, Gene Ontology (GO), and transcription factor and microRNA
motif gene sets obtained from the Molecular Signatures Database
(MSigDB), version 6.0. The microarray data have been submitted to the
National Center for Biotechnology Information Expression Omnibus under
accession number GSE119067 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE119067).
Statistics
Statistical analyses for microarray experiments are described above. For all
other analyses, two-tailed Student t tests were performed. The p values
.0.05 were considered NS.
Results
A new tool for defining Ikaros in peripheral T cell
differentiation and function
To study the function of Ikaros in mature T cells, an Ikflox mouse was
generated using Cre/lox technology in conjunction with the Mouse
Biology Project at University of California, Davis. Exon 8 (the last
translated exon) and the 39 untranslated region of the Ikaros gene,
Ikzf1, were flanked with loxP sites, such that this region of the gene is
deleted upon expression of Cre-recombinase. We chose this strategy
because it recapitulates that used to generate the Ikaros null mice
(15). This method also precludes insertion of a loxP site into 39 un-
translated region sequences, which could destabilize the mRNA
(Fig. 1A). Ikflox mice were crossed to Lck (distal promoter)-
Cre (hereafter referred to as Cre) transgenic mice, which targets
expression of Cre-recombinase and, therefore deletion of the
loxP-flanked sequences within the floxed Ikaros allele, to mature
T cells (26). This allows thymic selection events to occur with wild-
type levels of Ikaros. Western blot, intracellular flow, and qRT-PCR
analyses have demonstrated that Ikaros expression is efficiently
deleted in Ikflox 3 Cre peripheral CD4 T cells but not in immature
double positive thymocytes (Fig. 1B–D).
Characterization of thymocyte and splenocyte populations in
Ikflox mice
Ikaros null mice have profound defects in thymic T cell maturation
that result in decreased numbers of thymocytes, a dramatic increase
in the percentage of CD4 single positive thymocytes, and, by 5 wk
of age, outgrowth of leukemic T cells (15). Key to the success of
our conditional knockout model is that T cell maturation in the
thymus occurs normally.
Importantly, in Ikflox 3 Cre mice, double positive thymocytes
express wild-type levels of Ikaros (Fig. 1D). Deletion of Ikaros begins
once thymocytes have transitioned into the single positive stage in the
thymus but is not observed in the majority of T cells until they reach
the periphery (Fig. 1B–D). Because of this, numbers of thymocytes as
well as CD4/CD8 thymic profiles from Ikflox 3 Cre mice are indis-
tinguishable from their Ikflox (no Cre) counterparts (Fig. 2A). In the
spleen, percentages and numbers of CD8 T cells are normal, whereas
there is a slight, but significant, increase in those of CD4 T cells
(Fig. 2B). Percentages of B cells and myeloid cells were unaffected
(Fig. 2C).
Ikaros has been associated in activation and silencing of the genes
encoding CD8 and CD4, respectively, in thymocytes (27, 28). T cells
from Ikflox3 Cre spleens do not have significantly altered expression
of either, showing that Ikaros’ role in expression of CD4 and CD8
does not extend to the periphery (Fig. 2 and data not shown). Per-
centages of CD4+ effector memory (CD62LloCD44hi) and central
memory (CD62LhiCD44hi) cells (Fig. 3A), as well as percentages of
CD4 T cells expressing Foxp3 (regulatory T; Treg) and T-bet (Th1) do
not differ in spleens of Ikflox3 Cre and Ikflox (no Cre) mice (Fig. 3B).
There were negligible percentages of CD4 T cells expressing GATA3
(Th2) or RORgt (Th17) in spleens of either Ikflox 3 Cre or Ikflox
(no Cre) mice (data not shown).
Therefore, we can conclude that, in Ikflox 3 Cre mice, thymic
T cell maturation is not perturbed and splenic T cell populations are
similar to those observed in wild-type mice.
Ikflox 3 Cre T cells show decreased proliferation and survival
upon TCR stimulation
T cells require signal delivered by pathogen through the TCR
complex to undergo activation and differentiation events that drive
their role in the immune response. To investigate how lack of Ikaros
affects the ability of T cells to respond to TCR complex stimulation,
splenocytes from Ikflox 3 Cre and Ikflox (no Cre) mice were loaded
with the fluorescent proliferation dye CFSE and plated in the
presence of plate-bound anti-CD3 and soluble anti-CD28 (hereafter
designated anti-CD3/anti-CD28). At the end of the assay, cells were
stained with fluorescent Abs against CD4 and CD8 to define the
distinct T cell populations. Ikflox 3 Cre CD4 T cells did not pro-
liferate as well as Ikflox (no Cre) CD4 T cells, lagging by ∼2 cell
divisions (Fig. 4A). This held true over a range of anti-CD3 con-
centrations demonstrating that the observed decrease in prolifera-
tion was not due to an increased threshold of activation. Similar
results were observed for Ikflox3 Cre CD8 T cells (data not shown).
Next, CD4 T cells purified from the spleens of Ikflox 3 Cre and
Ikflox (no Cre) mice were plated with anti-CD3/anti-CD28 for
24–72 h to perform cell cycle analyses. At the end of the culture
period, cells were permeabilized and stained with propidium
FIGURE 1. Characterization of Ikaros conditional knockout mice. (A)
Schematic representation of floxed Ikzf1 locus showing placement of loxP
sites. Not to scale. (B) Western blot of Ikaros expression in splenic CD4
T cells from Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre; Cre2) mice. Two
bands detected by anti-Ikaros Ab represent Ik-1 and Ik-2 isoforms. Densi-
tometry readings for Ikaros bands normalized for levels of nucleolin (Nuc)
expression are 1.2 (Cre2) and 0.26 (Cre+). (C) qRT-PCR for Ikaros ex-
pression using cDNA from Cre+ (gray bar) and Cre2 (white bar) thymuses
or splenic CD4 T cells. Results are normalized to values for HPRT expres-
sion (n = 3). p , 0.01 for spleen, NS for thymus. Error bars represent 6
SEM. (D) Flow cytometric overlay histogram plots comparing levels of in-
tracellular staining for Ikaros in thymus (gated on CD4+CD8+ cells or CD4
single positive cells) and spleen (gated on CD4+ T cells) of Cre+ (solid line)
and Cre2 (dashed line) mice. Representative of 10 independent experiments.
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iodide, a fluorescent dye that intercalates into DNA thereby
allowing quantification of DNA content. By 48 h postactivation,
Ikflox 3 Cre CD4 T cell cultures showed decreased percentages of
cells entering S phase (p , 0.02) and increased percentages of
cells with sub-G0 amounts of DNA (p , 0.01) as compared with
Ikflox (no Cre) cultures (Fig. 4B). Therefore, we can conclude that
the reduced proliferative capacity of Ikflox 3 Cre CD4 T cells is
the result of their decreased ability to progress beyond G0/G1 and
their increased propensity to die. Taken together, these defects
resulted in an inability of Ikflox 3 Cre cultures to increase in
number over time (Fig. 4C). The defect in survival, but not pro-
liferation, could be reduced by addition of the caspase-3 inhibitor
Z-DEVD-FMK to the activation cultures (Fig. 4D), showing that
reduced proliferative capacity of Ikflox 3 Cre CD4 T cells was
not solely due to their increased propensity to die when stimu-
lated. It is important to note that Ikflox 3 Cre CD4 T cells show
normal upregulation of CD25 and CD40L upon activation
(Fig. 5A) proving that the defects observed upon TCR stimu-
lation are not due to grossly abnormal cells that cannot be
activated.
Thus, we can conclude that Ikaros is required for viability and
proliferation of CD4 T cells after activation, but is not required for
early activation events that promote upregulation of CD25 and
CD40L.
Early cytokine response is upregulated in the absence of Ikaros
Cytokines are the mediators of the CD4 T cell response. Their
expression is upregulated at the level of gene expression upon
TCR/coreceptor signaling. Therefore, expression of cytokine
genes was examined following activation (24 h with anti-CD3/
anti-CD28) of purified CD4 T cells from the spleens of Ikflox 3
Cre and Ikflox (no Cre) mice. Ikflox 3 Cre cultures showed in-
creased expression of a select set of cytokine genes, including
those encoding IL-2 (Il2; p = 0.033), IFN-g (Ifng; p = 4.2 3
1024), TNF-a (Tnf; p = 0.036), and GM-CSF (Csf2; p = 1.37 3
1025) (Fig. 5B). Many of these fall into the category of
proinflammatory effectors. There was no significant difference
in expression of the genes encoding IL-4 (Il4) or IL-17A
(Il17a), suggesting that Ikaros deficiency does not impact ex-
pression of all cytokine genes (Fig. 5B).
Expression of the activation-induced gene encoding IL-2Ra
(Il2ra) was also unaffected in the absence of Ikaros (Fig. 5B),
confirming the normal upregulation of CD25 discussed above
FIGURE 2. Ikflox3 dLck-Cre mice
have normal thymocyte populations
but display slight alterations in cell
populations in the spleen. Represen-
tative flow cytometric analyses of
CD4 and CD8 expression on the sur-
face of thymocytes (A) and spleno-
cytes (B) from Ikflox (no Cre; Cre2)
and Ikflox 3 dLck-Cre (Cre+) mice.
Bar graphs represent average cellu-
larity of thymus/spleen or percentage
of cell subsets as labeled from four
independent experiments. Error bars
represent 6 SEM. *p = 0.0058. (C)
Representative flow cytometric analy-
ses delineating B (B220+IgM+) and
myeloid (CD11b+Gr-1+ TCRb2) cell
populations in the spleens of Cre+ and
Cre2 mice. Bar graphs represent av-
erage percentage of cell subsets from
four independent experiments. Error
bars represent 6 SEM.
FIGURE 3. Ikflox 3 dLck-Cre mice show no evidence of increased
memory or differentiated CD4 T cell subsets in the spleen. (A)
Splenocytes from Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre; Cre2)
mice were analyzed by flow cytometry for surface markers CD4, CD62L,
and CD44 to identify central memory cells (Tcm; CD62L+CD44+) and
effector memory cells (Tem; CD62L2CD44+) within CD4+ gated T cells.
Bar graph shows average percentage of memory populations within the
CD4+ T cell population from three independent experiments. Error bars
represent 6 SEM. (B) Representative flow cytometry plots showing
expression of CD4/Foxp3 and CD4/T-bet within the splenocyte pop-
ulations from Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre; Cre2) mice.
Bar graph shows average percentage of each cell subset from three in-
dependent experiments. Error bars represent 6 SEM. All data shown are
from analyses of mice 6–8 wk of age.
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(Fig. 5A) These data suggest that lack of Ikaros predisposes cells
to enhanced expression of cytokines linked to inflammation at
early stages of activation.
Effect of conditional deletion of Ikaros on Th1 and Th2
lineage specification
CD4 T cells differentiate into T helper subsets after antigenic
stimulation through TCR. The cytokines present in their mi-
croenvironment are the major determinants in the decision to
commit to a specific lineage, as they promote expression of
lineage-specific master transcription factors (29). Th1 and Th2
cells were the first two identified T helper subsets. They are flip
sides of a coin, expressing factors that drive their own differ-
entiation while repressing the alternative fate. Previous reports
have suggested that in CD4 T cells that do not express Ikaros,
Th1 lineage differentiation is enhanced, whereas that of the
Th2 lineage is prohibited (17). This has been attributed, in part,
to the inability to repress expression of Tbx21, the gene
encoding T-bet, in the absence of Ikaros (17, 30). However, as
stated previously, these experiments used CD4 T cells from
animals with abnormal thymic T cell development that devel-
oped T cell leukemia.
To definitively assess how lack of Ikaros in mature T cells impacts
their ability to differentiate into Th1 and Th2 lineage cells, CD4
T cells from Ikflox 3 Cre and Ikflox (no Cre) mice were activated
with anti-CD3/anti-CD28 under Th1 (IL-12, anti–IL-4) and Th2
(IL-4, anti–IFN-g) polarizing conditions. First, the ability of cells to
respond to differentiation cues early in their differentiation process
was assessed by examining expression of T-bet and GATA-3, the
Th1 and Th2 lineage master regulators respectively, by intracellular
staining followed by flow cytometry at 24, 48, and 72 h post-
initiation of culture. Because deletion of Ikaros expression is not
complete within the CD4 T cell population, differentiation potential
of Ikaros-positive and Ikaros-negative cells in Ikflox 3 Cre cultures
were tracked.
There was no significant difference in levels of Th1 specifi-
cation in Ikflox 3 Cre and Ikflox (no Cre) CD4 polarization cul-
tures as assayed by percentage of cells expressing T-bet at
72 h postinitiation of culture (Fig. 6A). However, the Ikaros-
deficient subpopulation within the Ikflox 3 Cre cultures did
show delayed differentiation, with significant differences in
percentages of T-bet–positive cells at 24 and 48 h time points
(Fig. 6A). Inclusion of a cell viability dye in the stainings ensured
that the observed delay was not due to increased cell death in these
cultures.
The early stages of Th2 lineage commitment, as assessed by
levels of GATA-3 staining, also did not proceed normally. The
percentage of cells expressing GATA-3 was significantly reduced
in Ikflox 3 Cre compared with Ikflox (no Cre) cultures (Fig. 6A).
This was true for both the Ikaros-positive and Ikaros-negative
subpopulations. Previous reports using germline Ikaros mutant
mouse models have presented data suggesting a crucial role for
Ikaros in suppression of T-bet expression during Th2 differen-
tiation (17, 30). Therefore, we examined levels of T-bet to de-
termine if this defect underlies the decreased Th2 specification
observed in Ikflox 3 Cre cultures. However, there is no difference in
T-bet expression in Ikflox 3 Cre as compared with Ikflox (no Cre)
cultures at 24 h, when GATA-3 expression in the culture is already
FIGURE 4. Ikaros positively regulates the proliferative response to TCR/coreceptor signal. (A) Splenocytes from Ikflox 3 dLck-Cre (dashed
line) and Ikflox (no Cre) (solid line) mice were loaded with 5 mM CFSE and plated individually with 0.5, 2, or 8 mg/ml plate-bound anti-CD3/
soluble anti-CD28 for 72 h, followed by flow analyses. Histograms show CFSE fluorescence within the CD4+ gated population. Results shown are
representative of three independent experiments. (B) CD4 T cells from spleens of from Ikflox 3 dLck-Cre (Cre+) and from Ikflox (no Cre; Cre2)
mice were plated with 2 mg/ml plate-bound anti-CD3/soluble anti-CD28. Forty-eight hours postplating, cells were fixed in ethanol, followed by
propidium iodide staining and flow analyses. Bar graph shows average percentages of cells from four independent experiments that fall in the
following categories: sub-G0 (,2N DNA), G0/G1 (2N DNA), S (.2N but ,4N DNA), and G2/M (4N DNA). Error bars represent 6 SEM. *p ,
0.001, **p , 0.05. (C) Numbers of cells in Cre+ (solid lines) and Cre2 (dashed lines) CD4 T cell activation cultures at 0, 24, 48, and 72 h
postplating. Three independent experiments are shown. (D) CD4 T cells from spleens of Cre+ and Cre2 mice were plated and analyzed as
described in (B). To some cultures, caspase inhibitor was added (+inhibitor). Cell cycle profiles are from cells cultured for 48 h. Numbers show
percentages of cells in sub-G0 (,2N DNA), G0/G1 (2N DNA), S (.2N but ,4N DNA), and G2/M (4N DNA). Results shown are representative of
four independent experiments.
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reduced, suggesting that this cannot be the sole underlying cause
(Fig. 6B).
Interestingly, upregulation of T-bet expression is observed in
both Ikflox 3 Cre and Ikflox (no Cre) Th2 cultures by 48 h,
suggesting that this is a normal occurrence during Th2 differ-
entiation (Fig. 6B). However, by 72 h, cells in Ikflox (no Cre)
cultures had successfully downregulated T-bet expression,
whereas those in Ikflox 3 Cre cultures, both Ikaros-positive and
Ikaros-negative subsets, showed sustained expression (Fig. 6B).
Taken together, these data demonstrate that increased T-bet ex-
pression cannot explain the reduction in Th2 specification ob-
served at 24 and 48 h in Ikflox3 Cre cultures, and it also suggests
that the defect is not cell-autonomous.
After 6–7 d in Th1 and Th2 polarizing cultures, cells were
restimulated with PMA and ionomycin and examined for ex-
pression of the signature Th1 and Th2 cytokines, IFN-g and IL-4,
respectively, at both the protein and mRNA levels. Ikflox 3 Cre
Th1 cultures showed no significant difference in expression of
IFN-g compared with Ikflox (no Cre) Th1 cultures (Fig. 6C). The
same was true for IL-4 in Th2 cultures. There was a significant
increase in Ifng expression in Ikflox 3 Cre Th2 cultures, although
percentages of cells expressing IFN-g were much less than ob-
served in bone fide Th1 cultures (Fig. 6B, 6C).
Taken together these data show that although lack of Ikaros does
not significantly impact Th1 differentiation, it does result in
decreased Th2 specification within the first 72 h of polarization. We
hypothesize that in Ikflox 3 Cre Th2 cultures, a microenvironment
is created by inclusion of Ikaros-negative T cells that results in an
inability to repress expression of T-bet and IFN-g, which together
impact early events in Th2 differentiation. Yet, at least under
conditions of optimal Th2 differentiation as used in this study, this
does not result in skewing of cells toward the Th1 lineage, as
demonstrated by lack of reduction in the percentage of cells that
are competent to secrete IL-4 at day 6 of culture.
Effect of conditional deletion of Ikaros on Th17/iTreg cell axis
Th17 and iTreg cells are closely related CD4 T cell subsets with
diametrically opposed functions. They both depend on TGF-b for
their differentiation, suggesting that they use overlapping molecular
pathways. Presence of the inflammatory cytokine IL-6 in the mi-
croenvironment promotes downregulation of the transcription factor
Foxp3, the master regulator of the iTreg cell fate, blocking iTreg
cell and driving Th17 specification (31, 32). Studies using T cells
from germline Ikaros mutant mice have reported a role for Ikaros in
iTreg cell differentiation (19, 33) but differ in their assessment of
the importance of Ikaros for Th17 differentiation (18, 33).
To study how lack of Ikaros in mature T cells impacts their
ability to differentiate into iTreg and Th17 cells, purified splenic
CD4 T cells from Ikflox 3 Cre and Ikflox (no Cre) mice were
cultured with anti-CD3/anti-CD28 under iTreg cell (TGF-b, IL-2
anti–IL4, anti–IFN-g) or Th17 (TGF-b, IL-6, anti–IL-4, anti–IFN-g)
differentiation conditions. First, the ability of cells to respond to
differentiation cues early in development was assessed by examining
expression of RORgt and Foxp3, the Th17 and Treg lineage master
regulators, respectively, by intracellular staining followed by flow
cytometry at 24, 48, and 72 h postinitiation of culture. Th17 speci-
fication was unaffected by lack of Ikaros, whereas iTreg cell dif-
ferentiation was significantly decreased (Fig. 7A). Unlike the defect
in Th2 specification described above, the defect in iTreg cell
differentiation was cell intrinsic, being observed only in Ikaros-
deficient cells in Ikflox 3 Cre cultures (Fig. 7A). A previous re-
port has suggested that Ikaros represses expression of IL-21, a
driver of RORgt expression and Th17 differentiation, which could
underlie the defect observed in iTreg cell differentiation (33).
However, we did not observe abnormal expression of RORgt in
Ikflox 3 Cre iTreg cell cultures (Fig. 7B). This, together with the
observation that the defect in iTreg cell differentiation is only seen
within the Ikaros-negative subpopulation in Ikflox 3 Cre cultures
is strong evidence that increased secretion of IL-21, or any other
cytokine or factor, by Ikaros-negative cells could not underlie the
phenotype.
After 3–4 (for Th17 cultures) or 6–7 (for iTreg cell cultures) d in
polarizing cultures, cells were analyzed for expression of cytokines
after restimulation with PMA and ionomycin. Expression of the gene
encoding the hallmark Th17 cytokine IL-17A was not significantly
different in Ikflox 3 Cre and Ikflox (no Cre) Th17 differentiation cul-
tures (Fig. 7C). These data, together with the normal upregulation of
RORgt in Ikflox3Cre Th17 cultures at all time points (Fig. 7A), show
that lack of Ikaros does not impact specification into the Th17 lineage.
Coexpression of T-bet with RORgt in Th17 cells has been linked
to a pathological phenotype in some forms of autoimmune disease
(34–37). Because lack of Ikaros leads to the inability to suppress
expression of T-bet in Th2 cells (Fig. 5B), we hypothesized that
Ikaros-deficient Th17 cells could have this pathological pheno-
type. Indeed, a larger percentage of RORgt+ cells also expressed
T-bet in Ikflox 3 Cre as compared with Ikflox (no Cre) Th17 cul-
tures (Fig. 7D). High-level expression of the cytokine GM-CSF
and an “ex-Th17” phenotype defined by expression of IFN-g are
additional hallmarks of pathological Th17 cells associated with
FIGURE 5. Early analyses of CD4 T cells post–TCR activation show
normal activation but upregulated expression of select cytokines in
the absence of Ikaros. (A) Representative flow cytometric analyses of
splenocytes from Ikflox 3 dLck-Cre (Cre+) and Ikflox (Cre2) mice plated
with 2 mg/ml plate-bound anti-CD3/soluble anti-CD28 for 24 h showing
expression of the activation markers CD25 and CD40L within the CD4 T
cell subset. Boxed numbers in upper right quadrant of the plots shows
calculated percentage of CD4 T cells expressing the given marker. Bar
graph shows average percentage of CD4 T cells expressing CD25 and
CD40L from five independent experiments. Error bars represent 6 SEM.
(B) qRT-PCR of genes encoding GM-CSF (Csf2), IL-2 (Il2), IFN-g (Ifng),
CD25 (Il2ra), and TNF-a (Tnf) in Cre+ and Cre2 CD4 T cell cultures that had
been activated for 24 h. Values were first normalized to HPRT and then to
expression in Cre2 cultures (making Cre2 cultures equivalent to 1). Error bars
represent 6 SEM. *p , 0.001, **p , 0.05.
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autoimmune syndromes (38–43). In PMA and ionomycin
restimulated Ikflox 3 Cre Th17 cultures, there was significantly
increased expression of the genes encoding GM-CSF (p = 0.0375)
and IFN-g (p = 0.018) relative to that expressed in Ikflox (no Cre)
counterparts (Fig. 7E). In conclusion, although lack of Ikaros does
not impact Th17 specification, it causes a shift in the qualitative
nature of the Th17 cell response toward a pathological phenotype
associated with autoimmunity.
Deregulation of gene programs associated with inflammation
and autoimmunity in the absence of Ikaros
Tomore comprehensively examine the effect of loss of Ikaros in CD4
T cells, we undertook global analyses of gene expression in purified
resting (freshly isolated) and activated (anti-CD3/anti-CD28 for 24 h)
CD4 T cells from spleens of Ikflox 3 Cre and Ikflox (no Cre) mice.
Gene-set enrichment analyses (GSEA) of the microarray data re-
veals the overrepresentation of genes associated with inflammation
and autoimmunity in activated Ikaros-deficient CD4 T cells (Table I).
Interestingly, upregulation of gene sets and genes associated with the
response to type I IFN is also observed in resting (freshly isolated)
Ikflox 3 Cre CD4 T cells (Fig. 8A, 8B, Table II) (44).
Next, we wanted to determine the magnitude of upregulation of
IFN-stimulated genes (ISGs) in Ikaros-deficient T cells as compared
with what is observed during a bona fide type I IFN response. To
activate the type I IFN response, CD4 T cells from Ikflox 3 Cre and
Ikflox (no Cre) mice were treated with varying concentrations of
IFN-a for 4 h, followed by preparation of RNA. In some instances,
levels of overexpression in Ikflox 3 Cre resting T cells approximated
those observed in 10 U/ml (Oas2 and Parp12) or 100 U/ml (Ifitm3)
IFN-a–stimulated Ikflox (no Cre) CD4 T cells, as shown by levels of
three of the top deregulated ISGs (Fig. 8C).
To determine if increased expression of ISGs was due to the
presence of active IFN signaling due to an inflammatory environment
in the Ikflox 3 Cre mice, we undertook two approaches. First, we
examined Ikflox 3 Cre T cells for the presence of phospho-STAT1,
a downstream activator of both type I and type II IFNs using flow
cytometry (45). Intracellular staining with Ikaros Ab was per-
formed concurrently to identity the T cells (which would be the
Ikaros-negative subpopulation). Whereas we could detect phospho-
STAT1 in splenocytes activated with IFN-a ex vivo for 30 min, no
phospho-STAT1 was present in freshly isolated Ikflox 3 Cre
splenocytes that were fixed immediately upon isolation (Fig. 8D).
Second, we examined expression of ISGs in macrophages from
Ikflox 3 Cre mice, which would have intact Ikaros expression. We
observed no enhanced ISG expression relative to what is observed
in macrophages from Ikflox (no Cre) mice (Fig. 8E). Taken together,
these data show that the increased ISG expression in freshly isolated
Ikflox 3 Cre CD4 T cells occurs in the absence of active IFN sig-
naling and is not due to an inflammatory environment in the mouse,
which would also impact ISG expression in the macrophages.
Increased expression of the ISG program would be expected to
decrease the ability of a cell to be infected by virus. To determine if
FIGURE 6. Lack of Ikaros has limited effects on Th1 and Th2 differentiation. (A) CD4 T cells from Ikflox3 dLck-Cre (Cre+) and Ikflox (no Cre; Cre2) mice
were plated with anti-CD3/soluble anti-CD28 under Th1 or Th2 polarizing conditions. Cells were analyzed for expression of T-bet, GATA3, and Ikaros by flow
cytometry at 24, 48, and 72 h postculture. The three lines in the plots represent levels of expression of transcription factors in 1) the Cre2 culture (solid line), 2)
the Ikaros-positive subpopulation in the Cre+ culture (dashed line), and 3) the Ikaros-negative subpopulation in the Cre+ culture (dotted line). Results shown are
the average of three independent experiments. Error bars represent 6 SEM. The p values represent comparisons to values in Cre2 culture. (B) Flow cytometry
plots are representative of three independent experiments. Quantitated data are shown in line graph. Error bars represent 6 SEM. Cre2 (solid line), Ik+ Cre+
(dashed line), Ik2 Cre+ (dotted line). The p values represent comparisons to values in Cre2 culture. (C) CD4 T cells in Th1 and Th2 cultures were restimulated
with PMA and ionomycin in the presence of brefeldin A, followed by intracellular cytokine staining and flow cytometric analyses. Data shown are repre-
sentative of three independent experiments. The bar graph quantitates the result of qRT-PCR analyses of genes encoding IFN-g (Ifng) and IL-4 (Il4) in these
cultures. Values were first normalized to HPRT and then to expression in Cre2 cultures (making Cre2 cultures equivalent to 1). Error bars represent 6 SEM
(n = 3). *p , 0.01, **p , 0.05.
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Ikflox 3 Cre CD4 T cells are more resistant to viral infection, CD4
T cells from spleens of Ikflox 3 Cre and Ikflox (no Cre) mice were
infected with the recombinant virus rVSV-eGFP (25) for 24 h fol-
lowed by flow cytometric analyses. Cultures treated with IFN-a were
significantly less infected, demonstrating that signals provided by type
I IFN reduced infection rates in our model system (Fig. 9). Ikflox 3
Cre CD4 T cells were significantly less infected than their Ikflox
(no Cre) counterparts (Fig. 9). Significantly, the percentage of infected
cells in the Ikflox 3 Cre cultures was not significantly different from
those in IFN-a–treated Ikflox (no Cre) cultures, showing that the level
of infection was similar to that observed in cells undergoing a
strong induction of the type I IFN-induced gene program.
Taken together, these data show that lack of Ikaros induces a
robust derepression of the ISG program in T cells in the absence of
outside IFN-a signals.
Discussion
Although it has been known for more than a decade that Ikaros is a
critical factor for regulation of early developmental decisions at the level
of theHSCaswell as inT cellmaturation in the thymus, its role inmature
T cells is less well defined. Our new conditional knockout Ikaros mouse
model has now given us the tools to define an important role for Ikaros in
T cells as repressor of inflammatory gene programs, both at the level of
inflammatory cytokine gene expression and gene programs induced by
FIGURE 7. Ikaros is required for iTreg cell differentiation and suppresses the pathological Th17 phenotype. (A) CD4 T cells from Ikflox 3 dLck-Cre
(Cre+) and Ikflox (no Cre; Cre2) mice were plated with anti-CD3/soluble anti-CD28 under Th17 or iTreg cell polarizing conditions. Cells were analyzed for
expression of RORgt, Foxp3, and Ikaros by flow cytometry at 24, 48, and 72 h postculture. The three lines in the plots represent levels of expression of
transcription factors in 1) the Cre2 culture (solid line), 2) the Ikaros-positive subpopulation in the Cre+ culture (dashed line), and 3) the Ikaros-negative
subpopulation in the Cre+ culture (dotted line). Results shown are the average of three independent experiments. Error bars represent 6 SEM. The p values
represent comparisons to values in Cre2 culture. *p, 0.005. (B) Flow cytometric analyses of RORgt expression as assayed by intracellular staining in 3-d Th17
(dashed line) and iTreg cell (solid line) Cre+ and Cre2 cultures. Data shown are representative of two independent experiments. (C) qRT-PCR of gene encoding
IL-17A (Il17a) in PMA and ionomycin restimulated Th17 cultures. Each of the four lines represents an independent experiment consisting of one Cre+ and one
Cre2 culture. Values for levels of each transcript were first normalized to HPRT and then plotted as fold increased relative to expression in Cre2 cultures
(making Cre2 cultures equivalent to 1). (D) Flow plots showing expression of T-bet and RORgt in 3-d Th17 cultures as assessed by intracellular staining. Data
shown are representative of three independent experiments. (E) qRT-PCR of genes encoding GM-CSF (csf2) and IFN-g (ifng) in PMA and ionomycin
restimulated Th17 cultures. Each of the four lines represents an independent experiment consisting of one Cre+ and one Cre2 culture. Values for levels of each
transcript were first normalized to HPRT and then plotted as fold increased relative to expression in Cre2 cultures (making Cre2 cultures equivalent to 1).
Table I. In the absence of Ikaros, activated CD4 T cells display upregulation of pathways linked to inflammation and autoimmunity
Gene Set Name Gene Set Size ES NES Nominal p Value FDR q Value
Hallmark TNFA signaling via NFKB 192 0.67 2.72 ,0.001 0.0000
Hallmark IL-2 STAT5 signaling 196 0.59 2.41 ,0.001 0.0000
Hallmark IFN-g response 182 0.59 2.41 ,0.001 0.0000
Hallmark inflammatory response 189 0.58 2.37 ,0.001 0.0000
GO response to IFN-g 104 0.62 2.36 ,0.001 0.0000
Biocarta cytokine pathway 18 0.89 2.34 ,0.001 0.0000
KEGG type I diabetes mellitus 31 0.76 2.29 ,0.001 0.0001
Biocarta inflammatory pathway 25 0.77 2.20 ,0.001 0.0005
KEGG graft versus host disease 23 0.77 2.21 ,0.001 0.0006
KEGG allograft rejection 25 0.77 2.18 ,0.001 0.0010
GO response to IFN-b 20 0.79 2.11 ,0.001 0.0022
Hallmark IFN-a response 87 0.58 2.08 ,0.001 0.0030
GO negative regulation of viral genome replication 35 0.68 2.06 ,0.001 0.0037
KEGG autoimmune thyroid disease 27 0.69 2.02 ,0.001 0.0057
Results of GSEA analyses of microarray data for Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre) CD4 T cells activated with anti-CD3/soluble anti-CD28 for 24 h. In total, 1876
gene sets were significantly enriched in Cre+ relative to Cre2 CD4 T cells (FDR q , 0.25). Examples of enhanced biological processes, functions, and pathways are shown.
ES, enrichment score; NES, normalized enrichment score.
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type I IFNs. Deregulation of these programs in the absence of Ikaros
leads to altered Th phenotypes and crippled proliferative responses.
Our data demonstrate that peripheral T cells from mice with
germline Ikaros null mutations have different phenotypes from those
in which Ikaros is deleted after thymocyte maturation. Whereas CD4
T cells from Ikaros null mice are unable to differentiate into the Th2
and Th17 lineages, CD4 T cells from Ikflox 3 dLck-Cre mice show
no defect in upregulation of RORgt in response to Th17 differen-
tiation signals, and, whereas upregulation of GATA-3 is decreased,
Th2 specification can proceed. Ikflox 3 dLck-Cre Th2 and Th17
cultures also express wild-type levels of Il4 and IL17a, respec-
tively. These data suggest that Th2 and Th17 lineage differentiation
circuits are intact and do not depend on Ikaros. Lack of Ikaros has
also been associated with a hyperproliferative phenotype in CD4
T cells from Ikaros germline knockout mice. However, our data
suggest a contrary role with lack of Ikaros resulting in decreased
proliferation after T cell activation. The confounding factors of the
development of T cell leukemia as well as the defects in both
thymic positive and negative selection observed in germline Ikaros
null mice, which does not occur in our model system, likely con-
tributes to these disparate phenotypes.
Interestingly, data from studies using T cells from mice with
germline mutations in sequences within the DNA binding domain
of Ikaros leading to high level expression of “dominant negative”
FIGURE 8. Ikaros is required for suppression of ISG expression in T cells. (A) Heat map comparing expression levels of ISGs from transcriptome analyses
of freshly isolated CD4 splenic T cells from Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre; Cre2) mice. Results from three independent samples of each are
shown. All genes shown were enhanced in expression an average 1.4-fold or greater in Cre+ samples and differences were statistically significant (FDR
q,0.25, p # 0.02). (B) qRT-PCR analyses of representative ISGs to validate differences in resting CD4 T cells. Values for levels of each transcript were first
normalized to HPRT. Ratios of normalized Cre+ to Cre2 values are shown (n = 5). Error bars represent 6 SEM. *p # 0.01, **p , 0.005. (C) qRT-PCR
analyses showing expression of three ISGs in Cre+ and Cre2 splenic CD4 T cells that had been treated with 0, 1, 10, or 100 U of IFN-a for 4 h. Bar graph
shows average results from three independent experiments. Results are normalized to values for HPRT expression. Error bars represent 6 SEM. (D) Flow plots
showing expression of Ikaros and phospho-STAT1 (pSTAT1) in freshly prepared splenocytes from Cre+ and Cre2mice. Splenocytes treated with IFN-a served
as a positive control for pSTAT1 staining. In the plots representing Cre+ splenocytes, T cell populations would fall into the Ikaros-negative quadrants (upper and
lower left on plots). (E) qRT-PCR analyses showing expression of the three ISGs Oas2, Parp12, and Ifitm3 in peritoneal macrophages harvested from Cre+ and
Cre2 mice. Results are normalized to values for HPRT expression. Error bars represent 6 SEM.
Table II. In the absence of Ikaros, resting CD4 T cells upregulate expression of pathways linked to the response to type I IFNs
Gene Set Name Gene Set Size ES NES Nominal p Value FDR q Value
Hallmark IFN-a response 87 0.63 2.23 ,0.001 0.0033
Reactome IFN-a/b signaling 39 0.73 2.25 ,0.001 0.0055
GO response to type I IFN 41 0.67 2.14 ,0.001 0.0244
Reactome IFN signaling 115 0.55 2.06 ,0.001 0.0349
GO response to IFN-a 16 0.78 2.04 ,0.001 0.0358
Reactome RIG MDA5 mediated induction of
IFN-a/b pathway
53 0.59 1.99 ,0.001 0.0541
GO response to IFN-b 20 0.72 1.94 ,0.001 0.0756
Results of GSEA analyses of microarray data for freshly isolated Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre) CD4 T cells. In total, 152 gene sets were significantly enriched
in Cre+ relative to Cre2 CD4 T cells (FDR q , 0.25). Examples of enhanced biological processes, functions, and pathways are shown.
ES, enrichment score; NES, normalized enrichment score.
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Ikaros proteins demonstrated that they are able to differentiate into
Th2 cells ex vivo (30) and even show enhanced Th17 differenti-
ation (33). These studies, together with results reported in this
article, support the contention that although there is much to be
learned by the study of germline Ikaros null mice, particularly as
regards understanding mechanisms of human disease that are the
result of inherited genetic mutations, they are likely not the best
choice for parsing out the mechanistic role of Ikaros in mature
T cells.
Although, in our model, Ikaros-deficient T cells are able to attain
a Th17 fate, the Th17 cells that develop are qualitatively different
from their wild-type counterparts. First, a large percentage of cells
in the Ikflox 3 dLck-Cre cultures coexpress RORgt and T-bet,
which has been associated with Th17 cells with pathological
tendencies. Second, cells in Ikflox 3 dLck-Cre cultures display
significantly increased expression of the genes encoding IFN-g
and GM-CSF, cytokines linked to Th17-driven autoimmune and
inflammatory diseases such as autoimmune encephalomyelitis,
diabetes, autoimmune myocarditis, and colitis (38–43, 46). The
molecular pathways that underlie development of pathological
Th17 cells are largely unknown, although IL-23 signaling has
been shown to be important. IL-23 induces expression of both
IFN-g and GM-CSF in Th17 cells, which likely contributes to this
role (39, 43, 47). Our Th17 cultures did not contain IL-23, yet lack
of Ikaros has similar consequences. This suggests that IL-23
signaling in Th17 cells may impinge on Ikaros function, which
should be further explored. Enhanced expression of IFN-g and
GM-CSF is not relegated to the Th17 lineage and can be observed
as early as 24 h postactivation in non-polarized Ikflox 3 dLck-Cre
CD4 T cell cultures. In addition, genome-wide gene expression
analyses reveal that in 24-h activated Ikaros-deficient CD4 T cell
cultures, there is global enhancement of gene sets associated with
inflammation and autoimmunity, suggesting that this deregulation
occurs early and is not dependent on a particular Th cell differ-
entiation program. Taken together, these data define Ikaros as a
guardian of the inflammatory phenotype in T cells.
Using germline Ikaros mutant mice, we and others have reported
increased expression of T-bet in CD4 T cells cultured under Th2
polarizing conditions. It has been reported that Ikaros may be
involved in directly repressing expression of Tbx21 during Th2
differentiation. Interestingly, we observed that T-bet upregulation
is a normal event early in Th2 differentiation and lack of Ikaros
does not impact levels or frequency of T-bet expression up to 48 h
postinitiation of Th2 differentiation. Rather, Ikaros’ role appears
to be evident later in the process, when sustained T-bet expres-
sion is observed in Ikflox 3 dLck-Cre cultures as opposed to its
downregulation in Ikflox (no Cre) cultures. Despite this, Ikaros-
deficient CD4 T cells can attain the Th2 fate, albeit at a reduced
rate, as there is no effect on expression of IL-4 at later time points.
Although cells in Ikflox 3 dLck-Cre Th2 cultures also express
increased levels of IFN-g compared with Ikflox (no Cre) cultures,
the frequency of IFN-g–secreting cells is significantly lower than
that observed in bona fide Th1 cultures. However, taking into
consideration that T-bet expression is upregulated in response to
IFN-g (48), our data suggest that the inability to repress IFN-g
production (whose expression is enhanced by 24 h postactivation
in Ikflox 3 dLck-Cre activation cultures) is the likely mechanism
underlying sustained T-bet expression in Ikflox 3 dLck-Cre Th2
cultures. This model is supported by our previous report showing
that restoration of Ikaros expression using retroviral transduction
was able to suppress expression of IFN-g in Ikaros null T cells but
was unable to alter expression of Tbx21 (49).
Consistent with what has been reported using CD4 T cells from
Ikaros germline mutant mice, we observe a significantly reduced
ability of Ikflox 3 dLck-Cre CD4 T cells to differentiate into iTreg
cells. Due to incomplete efficiency of Ikaros deletion within the
CD4 T cell population in the spleen, our conditional knockout
model has provided insight into the mechanism underlying this
defect. Because decreased iTreg cell differentiation was observed
in Ikaros-negative, but not Ikaros-positive, cells in iTreg cell
differentiation cultures, this points to a cell-intrinsic defect rather
than increased secretion of cytokines that would suppress the
iTreg cell program. It has been reported that iTreg cells can have
unstable expression of Foxp3, resulting in generation of proin-
flammatory ex-Treg cells that can be destructive (50). Our data
cannot distinguish between reduced iTreg cell differentiation versus
reduced iTreg cell stability in the absence of Ikaros. Because Ikaros
associates with chromatin remodeling complexes (51), it is rea-
sonable to hypothesize that differentiation induced programs may
be unstable in its absence. Future studies are needed to differentiate
between these two mechanisms.
In a quest to define the mechanism underlying the proin-
flammatory phenotype observed in Ikflox3 dLck-Cre CD4 T cells,
global gene expression analyses were performed. These studies
used freshly isolated CD4 T cells from spleens of Ikflox 3 Cre and
Ikflox (no Cre) mice. Therefore, they would be a mixture of naive,
memory, Treg, and differentiated Th cell subsets. Ikflox 3 dLck-
Cre and Ikflox (no Cre) CD4 T cell populations are equivalent
based on assessment of defined markers for these populations.
Therefore, to capture the most differences and not rely on a sorting
strategy based on expression of surface markers whose expression
could be altered in the absence of Ikaros, we chose this approach.
Gene set enrichment analyses (GSEA) of these data revealed that
the most significant differences in freshly isolated Ikflox 3 Cre and
Ikflox (no Cre) CD4 T cells were in expression of gene sets as-
sociated with the response to type I IFNs. Enhanced expression of
ISGs in Ikflox 3 dLck-Cre CD4 T cells occurred in the absence of
type I IFN signaling in the T cells or an overt inflammatory en-
vironment in the animals, suggesting that Ikaros functions as a
repressor of this gene program in the absence of activating signal.
Could there be a link between the inappropriate activation of a type I
IFN response in resting Ikaros-deficient T cells and the proin-
flammatory phenotype of Ikaros-deficient activated T cells? Studies
with innate immune cells have provided conflicting results with some
studies reporting that type I IFNs restrain proinflammatory pathways
FIGURE 9. Lack of Ikaros renders cells comparably resistant to infec-
tion by virus as wild-type cells treated with IFN-a. CD4 T cells, purified
from the spleens of Ikflox 3 dLck-Cre (Cre+) and Ikflox (no Cre; Cre2)
mice, were cultured with or without 10 U/ml IFN-a, followed by infection
with the recombinant virus rVSV-eGFP. Twenty-four hours postinfection,
cells were analyzed for expression of eGFP by flow cytometry. Shown are
representative plots from two independent experiments, with two cultures
per condition per experiment. Bar graph shows compilation of all data.
Error bars represent 6 SEM. There was no significant difference in per-
centage of cells infected in Cre+ cultures without IFN-a versus Cre2
cultures with IFN-a (p = 0.2615) (n = 4). *p = 0.0016. For both Cre+ and
Cre2 cultures, addition of IFN-a resulted in a significant decrease in
percentage of cells infected relative to that observed in cultures with no
IFN-a (for Cre+ cultures, p = 0.011; for Cre2 cultures, p = 0.00125).
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and others demonstrating that they enhance these pathways. Reports
supporting the latter include a mouse model of RSV infection in the
lung, where it was discovered that type I IFNs serve to amplify the
proinflammatory response, including production of IFN-g, GM-CSF,
and TNF-a (52). In addition, a recent report has shown that in human
macrophages, type I IFNs prime the chromatin associated with
proinflammatory cytokines to enable robust transcriptional responses
to weak signals (53). Therefore, there are intriguing data that serve as
a precedent to investigate this possibility further.
Why would T cells need to limit expression of ISGs? The response
to type I IFNs results in establishment of an antiviral state, which is
characterized by expression of proteins that interfere with the viral life
cycle. These include proteins involved in RNA degradation, transla-
tional inhibition and apoptosis (54). Therefore, not surprisingly, ex-
pression of ISGs can result in antiproliferative and proapoptotic
phenotypes. We have shown that Ikflox 3 dLck- Cre CD4 T cells
proliferate less and die more than their wild-type counterparts when
activated. We hypothesize that the elevated expression of ISGs in
Ikaros-deficient resting T cells contributes to this phenotype. ISG
expression also must be controlled after the immune response has
peaked because persistent type I IFN signaling can impair host im-
munity, leading to virus persistence (55–57). Taken together, it is
clear that a productive adaptive immune response requires a tightly
controlled response to type I IFNs and our data support the conclu-
sion that Ikaros is required for this preventative roadblock.
Ikaros gene variants have been associated with autoimmune and
inflammatory diseases in humans. Our data have revealed likely
mechanisms that could underlie this. However, Ikflox 3 dLck-Cre
mice do not display overt symptoms of spontaneous autoimmu-
nity. It is important to note that we have not yet conducted targeted
studies to address this (i.e., looked for autoantibodies). Also, most
models of spontaneous autoimmunity require time to develop and
our studies have focused on young mice (,3 mo of age). Future
studies will more carefully investigate this.
In conclusion, we have identified Ikaros as the center of a complex
web of events important for a regulated immune response. Ikaros
deficiency results in an inability of CD4 T cells to attain an iTreg cell
fate as well as drives the T cell response down an inflammatory
pathway, providing insight into how its activity is crucial to maintain
T cell homeostasis and prevent autoimmune and inflammatory
diseases. We also have defined Ikaros as a repressor of the type I
IFN–stimulated gene program, another key pathway whose dereg-
ulation is linked to autoimmunity. It will be important to translate
these findings into in vivo mouse models of autoimmunity as well
as define these roles for Ikaros in human cells and disease.
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